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ABSTRACT OF DISSERTATION

POLYSUBSTANCE OPIOID USE IN A JUSTICE-INVOLVED POPULATION: AN
ANALYSIS OF PATTERNS AND REENTRY OUTCOMES

The public health crisis surrounding opioid use is pronounced among justice-involved
populations, who face high rates of overdose mortality as well as HIV, and hepatitis C due to
injection drug use. The majority of opioid-related overdoses are due to polysubstance use (PSU),
and a better understanding of the prevalence and patterns of PSU are necessary in order to inform
interventions. This dissertation project has three aims: (1) understand the patterns of opioid PSU
among a justice-involved population, (2) identify PSU patterns most at-risk for post-release
relapse, and (3) examine engagement in post-release health service utilization. Post-release aims
are guided by the Gelberg Behavioral Model of Vulnerable Populations.
This project utilizes secondary data from the Criminal Justice Kentucky Treatment
Outcome Study, a Kentucky Department of Corrections funded two-wave longitudinal study of
individuals who participated in substance abuse treatment programming while incarcerated.
Latent profile analysis is used to determine the patterns of pre-incarceration opioid PSU in aim 1.
Analyses for aims 2 and 3 examine PSU profiles, along with variables drawn from the Behavioral
Model for Vulnerable Populations, in order to predict important reentry outcomes of relapse and
health service utilization 12-months post-release in a series of logistic regressions.
Six unique profiles of opioid PSU were found among the current justice-involved
population, which faced disproportionate risk of adverse outcomes at follow-up. Findings indicate
heterogeneity of opioid use among a justice-involved population. The role of mental and physical
health in PSU severity is also highlighted. Further, results from post-release analyses indicate that
a continuum of risk exists among PSU such that PSU patterns are unique and important predictors
of post-release outcomes which can be used to inform interventions during incarceration. The
importance of accounting for vulnerability as conceptualized in the Behavioral Model for
Vulnerable Populations is also discussed.
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CHAPTER 1. BACKGROUND AND INTRODUCTION
1.1

Introduction to topic
The opioid epidemic has taken an excess of 700,000 lives since 1999 (CDC, 2018).

Overdose deaths due to opioids continue to increase, with opioids involved in 67.8% of all
overdose deaths in 2017 (CDC, 2018). One in 10 individuals who died from an overdose were
recently released from a criminal justice institution (Mattson, 2018). Recent data suggest the
majority of individuals with opioid use disorders have recent justice involvement (Winkelman,
Chang, & Binswanger, 2018). Complicating this issue is the involvement of multiple substances,
known as polysubstance use (PSU), and the subsequent involvement of PSU in overdose
fatalities.
This dissertation research examines pre-incarceration patterns of opioid PSU in order to
advance understandings of PSU among justice populations. The advanced statistical approach of
latent profile modeling is utilized to provide insights into the severity of PSU among the current
population. Further, the utility of pre-incarceration PSU opioid patterns as predictors of postrelease behaviors is examined.
Deaths due to overdose from prescription opiates (PO) have increased since the 1990s, but
trends indicate the increase is not due to an increasing number of users (Kandel, Hu, Griesler, &
Wall, 2017). Rather, the prevalence of PSU with PO use has increased (Kandel et al., 2017).
Over a twelve-year period, the prevalence of PSU related overdoses with PO increased from 44%
to 58% (Kandel et al., 2017). Deaths due to PO in combination with heroin tripled and deaths in
combination with benzodiazepines and alcohol increased by a factor of 1.7 and 1.6 respectively
(Kandel et al., 2017).
PSU is incredibly dangerous. For example, co-use of benzodiazepines and opioids
decreases oxygen saturation leading to respiratory depression (Darke, 2014). Despite the
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increased risk for overdose, the regular co-use of benzodiazepines and opioids is common. The
rate of co-use of benzodiazepines is approximately 70% among users of heroin as well as
methadone-maintenance and buprenorphine-maintenance patients (Jones et al., 2012). The
combined use of opioids and cocaine is lethal as well, often due to the fact that the combination
delays the effects of opioids causing individuals to believe they can consume increased and
ultimately deadly amounts (Guzman & Ettenberg, 2004; Leri, Bruneau, & Stewart, 2003).
The most recent data available from CDC indicates that 18.5% of opioid deaths involved
both PO and illicit opioids (Mattson, 2018). Further PSU includes co-use of benzodiazepines
(44%) and cocaine (35%) with PO and illicit opioids (Mattson, 2018). An increasing number of
overdose deaths are due to synthetic opioids, primarily illicit fentanyl (Jones, Einstein, &
Compton, 2018). Deaths from synthetic opioids increased from 14% in 2010 to 46% in 2016,
with 80% of these deaths involving another substance such as other opioids, cocaine,
benzodiazepines, or alcohol (Jones et al., 2018).
Among individuals who use heroin, PSU is common, such that 96% of users report using at
least one other substance and 61% report using at least three different substances, including
meeting the criteria for abuse or dependence for more than one substance (Jones, Logan,
Gladden, & Bohm, 2015). PSU is also common among individuals who illicitly use methadone
and buprenorphine, such that individuals who engage in PSU may be more likely to divert opioid
substitution therapies (Bretteville-Jensen, Lillehagen, Gjersing, & Andreas, 2015).
Motivations for PSU likely differ by substances and by PSU method. PSU ingestion can
occur simultaneously, sequentially, or via regular interval co-use. The combination of two or
more substances during simultaneous PSU may produce unique or preferred effects that each
drug does not create individually or serve a particular purpose as in the case of self-medication
(Leri et al., 2003). For example, simultaneous PSU of heroin and methamphetamine (frequently
referred to as “goofballs”) has been increasing over the past decade (Al-Tayyib, Koester,
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Langegger, & Raville, 2017) with some reporting that the combination intensifies the effect of
low-purity heroin (Meacham et al., 2016).
Sequential PSU is similar to, yet unique from, simultaneous PSU. Motivations for
sequential use (i.e., use of one substance followed by another) can include aversion, the use of
one substance serves to reduce negative symptoms of the other- or reinforcing. For example,
sequential use of heroin and cocaine is stated to produce a more rewarding “high.” Sequential use
of heroin and cocaine is associated with injection drug use (IDU) risk practices such as frontloading and back-loading (Auerbach, Wypijewska, & Brodie, 1994). Additional research
indicates that heroin and sequential cocaine PSU eases withdrawal symptoms when opioid effects
terminate (Leri et al., 2003).
Regular interval PSU varies greatly and can be motivated by reinforcement, aversion, or
dependence. As an example, individuals may use stimulants in the morning or throughout the
week to stimulate their mood and productivity yet use sedatives in the evenings to “come down”
or relax (Ellinwood, Eibergen, & Kilbey, 1976). Regular interval PSU increases likelihood of
multiple substance use dependencies (Ellinwood et al., 1976; J. D. Jones, Mogali, & Comer,
2012) as well as adverse outcomes such as overdose (Jones et al., 2012). Regular interval use of
benzodiazepines with opioids can be motivated by the reinforcing effects by which
benzodiazepines amplify opioid intoxication (Chen et al., 2011; Jones et al., 2012).
Common PSU patterns of returning citizens associated with elevated risk for overdose
include opioids and cocaine as well as cocaine and other narcotics (Binswanger et al., 2013). The
most recent data suggest that 58% of state prisoners and 63% of jail inmates meet criteria for drug
dependence or abuse, compared with only 5% of the general population (Bronson, Stroop,
Zimmer, & Berzofsky, 2017). Studies have found 30-74% of currently incarcerated individuals
report using more than one substance prior to incarceration (Kubiak, 2004; Lo & Stephens, 2000).
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For individuals leaving the justice system, the reentry period is one of increased overdose
risk (Binswanger et al., 2012). Risk of overdose is highest in the initial weeks post-release owing
to reduced tolerance following periods of abstinence, and opioids were found to be involved in
59% of overdoses in one recently released sample (Binswanger, Blatchford, Mueller, & Stern,
2013). Among the same formerly justice-involved sample, 56% had more than one substance
involved in their overdose indicating substantial PSU prevalence. Despite risk, justice-involved
populations represent a vulnerable population whose PSU prevalence and patterns have yet to be
fully understood.
1.1.1

What we know and the utility of latent variable analysis
It is important to understand PSU given the associated risks, yet studying the topic is not

necessarily straightforward owing to the multiple modes of consumption and possible
combinations of substances involved. Statistical techniques such as cluster modeling and latent
class analysis have emerged as ideally suited to analyze PSU given their inductive approach.
Latent class analyses are person-centered approaches, used to create subgroups known as classes- or profiles in the case of continuous indicator variables- based on patterns from the data (Collins
& Lanza, 2010). In these analyses, individual characteristics, such as PSU patterns and
preferences, are central to the investigation compared to variable centered approaches (e.g., factor
analysis) where the structure is assumed to hold for all individuals (Collins & Lanza, 2010).
When dichotomous or ordinal indicators are used, latent class analysis (LCA) is performed while
latent profile analysis (LPA) uses continuous indicators. As an example, classes created from
LCA would include several substance indicators (yes/no) if an individual reported previous 30day use. For LPA, the number of days an individual used each substance would be used to create
the profiles.
It is advantageous to utilize LCA/LPA techniques for exploring the topic of PSU as it
allows the heterogeneity of substance patterns to be revealed inductively, as opposed to the
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researcher deciding which patterns should exist and deductively imposing them. The method has
grown in popularity among researchers of PSU (e.g., Agrawal, Lynskey, Madden, Bucholz, &
Heath, 2007; Betts et al., 2015; Harrell, Mancha, Petras, Trenz, & Latimer, 2012; Trenz et al.,
2013; Wu et al., 2011). Due to the high rate of overdose deaths in the current opioid epidemic, it
is important to highlight what existing understandings of opioid-PSU exist.
Given the utility of LCA/LPA to understand PSU, a systematic review of relevant studies
was conducted. EBSCOhost was searched using the keywords “latent (class) analysis” AND
“substance use” AND prefix “opi.” The resulting list was 44 studies, excluding duplicates.
Articles were also identified through secondary sources (i.e., searching reference lists of included
articles).
Inclusion criteria included (1) population of interest: adults ( adolescents and college
students were excluded), (2) substance use measurement: substance use must be self-report or
measured based on actual behaviors as opposed to studies relying on DSM criteria (3) publication
status: peer-reviewed primary studies only (commentaries and other such publications were
excluded), (4) method: the primary method must be a form of latent class analysis, (5) language:
all studies had to be published in English. The final resulting sample was 22 studies (see Table 1).
The 22 studies varied greatly in terms of populations included, and many of the studies
were in other countries, including Australia (n=5; Betts et al., 2016; Connor et al., 2013; Kelly et
al., 2014; Nielsen et al., 2011; Quek et al., 2013), South Africa (n= 1; Trenz et al., 2013), the
United Kingdom (n=2; Melendez-Torres, Bourne, Hickson, Reid, & Weatherburn, 2018),
Norway (n=1; Gjersing & Bretteville‐Jensen, 2018), Spain (n=1; Fernández-Calderón et al.,
2017), and Canada (n=2; Patra, Fischer, Maksimowska, & Rehm, 2009; Roy, Richer, Arruda,
Vandermeerschen, & Bruneau, 2013). Thus, the majority of prior studies have examined opioid
PSU in other countries; further understandings of PSU in a U.S. population, given the complex
opioid epidemic unique to the United States, is warranted.
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The LCA indicators varied significantly across studies (see Table 1). Substance use
histories varied in terms of time-span measured, ranging from lifetime use (Wu et al., 2011) to
prior 30-day use (Connor et al., 2013; Fong, Matusow, Cleland, & Rosenblum, 2015; Green,
Black, Serrano, Budman, & Butler, 2011; Harrell et al., 2012; Morley, Lynskey, Moran,
Borschmann, & Winstock, 2015; Parsons, Starks, Millar, Boonrai, & Marcotte, 2014; Patra et al.,
2009). Further, studies varied in latent indicators included for latent class construction. Studies
asked respondents about use of single substances, use of specific combinations (e.g., speedball
use), and others were more specific and account for route of administration (e.g., inject heroin).
The fewest latent indicators used for class creation were six substances (Ramo, Grov, Delucchi,
Kelly, & Parsons, 2010) and sixteen substances were the greatest number of indicators used
(Betts et al., 2015; Patra et al., 2009). While one study focused on substances by specific brand
name (Patra et al., 2009), the majority were concerned with broader categories (e.g., tranquilizers)
to capture a wider range of substance-use behaviors.
Studies varied in operationalization of indicators as well. The majority (82%) relied on
dichotomous measurements of use to construct classes. These range from collapsed ordinal
measures (e.g., frequent use versus infrequent) to simple yes/no indicators. Three studies used
ordinal indicators measuring frequency of use to construct classes (Betts et al., 2015; Feaster et
al., 2016; Gjersing & Bretteville‐Jensen, 2018). Only one of the studies utilized a continuous
count of days used (Parsons et al., 2014).
The resulting latent classes indicate that patterns vary substantially, owing to latent class
construction. However, there are some similarities to note. Most notably is the existence of
opioid-stimulant classes. Predominately these classes include cocaine and heroin use patterns
(Harrell et al., 2012; Kuramoto, Bohnert, & Latkin, 2011; Meacham et al., 2015; Patra et al.,
2009; Roy et al., 2013). Additionally, while the patterns of use may vary due to inclusion, all
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latent results have a class that is categorized by diverse substance use (i.e., heterogenous PSU)
and more extensive substance use than other classes.
The current composition of opioid LCA studies reveals important information, critical to
the studies of PSU. However, two issues remain. First, the implications of PSU are not entirely
clear. While the majority of studies examine prior 30-day use, an indicator more likely to
accurately reflect PSU patterns, other studies utilize dichotomous indicators over several months,
yearly, or lifetime time-spans. While even one instance of PSU can be dangerous, it remains
unclear if studies measuring multi-month, yearly, or lifetime indicators of substance use are
accurately capturing PSU patterns. For example, if an individual used marijuana three months ago
but drank alcohol last week, are they truly an at-risk polysubstance user? Studies examining prior
30-day use of multiple substances are more likely capturing the public health concern of PSU.
Further, studies that dichotomize ordinal indicators (e.g., more than once a week versus all other
use) are more apt to capture riskier PSU patterns. The next step for PSU studies would be to
include continuous indicators for LPA, to more accurately understand the likelihood of
overlapping substance use within a month for an individual. Studies that include variables
specific to PSU, such as measuring popular drug combinations, are also beneficial. However, for
studies of PSU to advance long-term, construction of PSU-specific screening and assessment
tools will need to be adapted.
The second limitation is the lack of justice-involved populations and justice covariates
among opioid PSU LCA studies. Of the studies included in Table 1, only two included any
account of justice involvement. Betts et al. (2016) and Green et al. (2011) included variables of
justice involvement and examined association of classes with justice variables. Results indicate
that more severe PSU classes had higher likelihood of justice involvement. Owing to sampling
techniques it is likely that many of the studies included formerly justice-involved populations.
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Explicit consideration through covariates or examination of PSU patterns among justice
populations, given their higher prevalence of substance use, is warranted.
The current research addresses these limitations by utilizing 30-day continuous indicators
of substance use to examine the polysubstance opioid patterns of a justice-involved sample.
Measures of substance use in the 30-days prior to incarceration are used in latent profile creation
in order to reveal PSU patterns that are expected to be more severe, given the substance use
histories of justice-involved populations.
1.1.2

Justice-involved populations as a vulnerable population
Many of the significant associations of PSU are more prevalent in justice-involved

populations, placing this population at disproportionate risk. Similar to PSU individuals, justiceinvolved individuals are more likely to have lower levels of education and complex histories of
physical and mental health problems (Shane Darke & Hall, 1995; Harlow, 2003; James & Glaze,
2006; Mallik-Kane & Visher, 2008; Martinotti et al., 2009).
A greater number of mental health comorbidities is associated with increasing number of
substances used (Borges, Walters, & Kessler, 2000; Connor et al., 2013; S. Darke & Ross, 1997;
Hakansson, Schlyter, & Berglund, 2011; Wu et al., 2011). Since mental health disorders are
more common among justice-involved individuals (James & Glaze, 2006), the relationship of
PSU with mental health comorbidity may be even more pronounced among this population. The
same is true of physical health comorbidities such that both tend to be poorer among PSU and
justice-involved populations (Carlson et al., 2014; Feaster et al., 2016; Mallik-Kane & Visher,
2008; Patra et al., 2009; Quek et al., 2013). There are also significant associations of certain PSU
patterns with IDU and hepatitis C (Harrell et al., 2012; Monga et al., 2007; Patra et al., 2009;
Roth et al., 2015).
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Co-occurring mental health psychopathology and physical health comorbidities also
complicate the reentry process. Approximately three-quarters of justice-involved individuals with
a mental health problem have co-morbid substance dependence or abuse (James & Glaze, 2006).
Individuals with depression, anxiety, and other mental health conditions may return to substance
use post-release for complex reasons including self-medication (Binswanger et al., 2012; Hser,
2007) and disruption to mental health medications post-release (Binswanger et al., 2012).
Justice-involved populations have poorer health than general populations (Freudenberg,
2001). Greater than 1/3 of individuals in prisons and jails have a chronic medical condition
(Wilper et al., 2009), including higher likelihood of conditions such as hypertension asthma,
cervical cancer, and hepatitis (Binswanger, Krueger, & Steiner, 2009). Further, continuity of care
upon reentry is difficult to manage due to the complexities in finding employment and housing,
lack of social support, difficulties obtaining insurance, and lack of social services (Mallik-Kane &
Visher, 2008; Petersilia 2008). Overall, the reentry period is a complicated one for individuals
returning to the community. Individuals with substance use histories, and PSU histories, are likely
to experience barriers in their attempts to avoid post-release substance use and appropriately
manage comorbid conditions.
Pronounced health problems are further difficult to manage post-release when
unemployment and economic distress are considered. Justice system involvement is concentrated
in the most disadvantaged communities (Western, 2014). The majority of individuals enter
prisons and jails with significant economic hardship, including 1 in 7 individuals with a substance
use disorder reporting pre-incarceration homelessness (Mumola & Karberg, 2006). Pre-treatment
unemployment is extremely common among individuals who use opioids (Platt, 1995.). While
employment has been demonstrated to be an important protective factor against relapse (Evans,
Hahn, Lum, Stein, & Page, 2009; Kadam, Sinha, Nimkar, Matcheswalla, & De Sousa, 2017;
Steensma, Boivin, Blais, & Roy, 2005) and recidivism (Apel & Horney, 2017; Bunting et al.,
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2019), there are significant barriers to successful employment for individuals who are reentering
the community. It is difficult to focus on recovery and health when faced with the competing
needs of general welfare.

1.2

Dissertation Research
Research is needed to understand the PSU patterns and prevalence among justice-involved

samples. While research of justice-involved populations indicate that this population has
increased risk factors and likelihood for PSU, the patterns of PSU among justice-involved
populations are unclear. While LCA research has identified possible PSU patterns among general
(e.g., Carlson et al., 2014; Quek et al., 2013) and at-risk populations (e.g., Kuramoto et al., 2011;
Meacham et al., 2016), justice populations have been excluded from research thus far.
The dissertation research is also interested in two important reentry outcomes related to
health of justice populations. Given that post-release substance use complicates reentry processes,
understanding the pre-prison PSU patterns and the subsequent post-release effects of these
patterns will reveal insights to inform future interventions. Substance use is typically highest
during periods of offending (Fisher et al., 2014), and involvement with the justice system
provides a key point for intervention. Further, previous research indicates the likelihood that PSU
populations have poorer health and are more likely to have comorbid physical and mental health
conditions (Betts et al., 2015; Shane Darke & Hall, 1995; James & Glaze, 2006; Mallik-Kane &
Visher, 2008). Ensuring these populations have appropriate linkage to health services post-release
and understanding barriers to care is additionally important. Pre-incarceration PSU patterns’
predictive value of post-release health service utilization can facilitate reentry planning.
To that end, this dissertation aims to expand on previous research through three
contributions:
(1) Understanding the prevalence and patterns of PSU among a justice-involved sample,
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(2) Examining the association of PSU patterns with post-release behaviors, and
(3) Improving upon existing methodologies through the utilization of LPA and
continuous substance use indicators
Through completion of these goals, the dissertation provides the foundation for a trajectory of
PSU research. By increasing knowledge of the intersection of PSU and justice-involvement,
including relevant methodologies with which to study the phenomena, the dissertation provides
the framework for the next phase of research aimed at development of screening and assessment
tools specifically created to capture PSU patterns.
1.2.1

Research Questions
The dissertation uses a three-paper format to address the following topics:

Chapter 2, “Paper 1: Heterogenous Opioid Use Among Justice-Involved Individuals: A Latent
Profile Analysis of Pre-Incarceration Polysubstance Opioid Use,” uses latent profile analysis to
answer the following research questions:
RQ1: What are the pre-incarceration polysubstance opioid patterns of a justice-involved
population in Kentucky?
RQ1.1: How are polysubstance opioid profiles of a justice-involved sample associated
with various sociodemographic, mental and physical health, and criminal justice histories?
It is hypothesized that polysubstance profiles of a justice-involved sample will have similarities to
general population PSU, yet be unique in terms of (1) severity or (2) new emerging profiles.
Further, relevant associations are likely to yield similarities to general populations, while likely
being more pronounced due to the likelihood of PSU populations to be represented by
characteristics that are inherent to justice-involved populations (e.g., mental health
comorbidities).
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Chapter 3, “Paper 2: Return to Substance Use: A Post-Release Examination of Polysubstance
Use,” utilizes logistic regression of baseline and follow-up data to address the following research
question:
RQ2: Which polysubstance profiles are at increased risk for post-release relapse?
It is expected that profiles with diverse PSU (i.e., more substances used, higher PSU) will be at
increased risk for relapse, given the association of these profiles for justice-involvement in
general populations.
Chapter 4, “Paper 3: Post-Release Health Service Utilization: An Application of the Behavioral
Model of Vulnerable Populations to a Polysubstance Population,” examines health service
utilization post-release through logistic block models to answer the following question:
RQ3: Which polysubstance profiles engage in post-release health care?
More diverse PSU patterns are associated with poorer physical and mental health, but how this
relates to consumption of services is unclear. It is hypothesized, therefore, that those profiles
shown in paper 1 (Chapter 2) to have the poorest health will be more likely to consume various
post-release care services simply due to increased need.
Chapter 5 will provide an overview of findings, consideration of all papers (1-3) collectively,
implications for interventions and policy, as well as directions for future research.
1.2.2

Description of data
Data for the three papers are from the state-mandated treatment outcome study of

substance abuse programming called the Criminal Justice Kentucky Treatment Outcome Study.
The study is ongoing since 2005 through a collaboration with the KY Department of Corrections
and the University of Kentucky’s Center on Drug and Alcohol Research.
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Data include both baseline assessments (Chapter 2) and follow-up surveys (Chapters 3 &
4). Baseline assessments are completed upon intake to substance abuse programming while
follow-up surveys occur 12-months post-release. Detailed information regarding the study,
sampling, and inclusion criteria are included in appropriate sections of each paper.
1.2.3

Covariate selection guided by the Behavioral Model for Vulnerable Populations
In Chapters 3 and 4 examining post-release health behaviors and health services

utilization, covariate selection is guided by the Behavioral Model for Vulnerable Populations
(Gelberg, Andersen, & Leake, 2000). A prior Behavioral Model by Andersen (1995) was
expanded to include factors specific to vulnerable populations, identified as those who experience
a greater risk of poor health due to differential exposure to risk factors. The framework identifies
characteristics that lead to health service utilization or health behaviors in the three domains of
(1) predisposing factors, (2) enabling factors, and (3) need factors which are further dichotomized
into categories based on relevancy to (1) traditional or (2) vulnerable populations. A diagram is
provided in Chapter 3 (paper 2) and Chapter 4 (paper 3).
Predisposing factors include demographic characteristics, or factors that exist prior to a
health need. Traditional predisposing factors include age, race, gender, marital status, or
employment. Vulnerable predisposing factors include homelessness (housing status),
incarceration history, or childhood characteristics (e.g., foster home history).
Enabling factors include resource characteristics, or those which affect one’s ability to
secure resources or care. In the traditional domain, this would include variables such as insurance
status or social support. In the vulnerable domain, variables could include public benefit receipt,
community resources, or disability status.
Need factors are the health conditions of general (for traditional) or specific vulnerable
populations. Traditional need factors would include general health problems whereas vulnerable
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need factors would be specified to the population studied, such as human immunodeficiency virus
(HIV) or sexually transmitted diseases.
Previous research has examined the Behavioral Model for Vulnerable Populations among
incarcerated populations (Glover, 2017; Krishnan et al, 2013; Meyer e al., 2012; Oser et al., 2016;
Victor et al., 2017) and found the vulnerable domains to be robust predictors of health service
utilization. These studies are generally limited to specific subpopulations, such as previously
incarcerated women or individuals with HIV, thus lacking a broader focus on reentering
populations more broadly. Recently released persons who use opioids are a vulnerable population
with greater risk of poor outcomes and exposure to risk factors. To account for this, covariate
selection and a secondary aim of examining the relevance of the vulnerable domain in predicting
post-release relapse and service utilization was included in papers 2 and 3. Further discussion of
the framework is included in the relevant section of these papers.
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Table 1.1Overview of the 22 studies included in the review
Citation

Sample

Latent indicators

Population

Frequency Measurement Results- latent classes
of use

Australia, SEP
convenience
sample as part
of Illicit Drug
Reporting
System (20112013
combined)
N=2,677

heroin,
methamphetamine,
cocaine, cannabis,
methadone,
buprenorphine,
buprenorphine-naloxone,
morphine, oxycodone,
other Rx opioids,
quetiapine, alprazolam,
other benzodiazepines,
prescription stimulants,
over the counter opioids,
alcohol

Previous
5 months

Ordinal from
daily to less
than monthly
(4 intervals)

(1) methadone/heroin,
low PSU (2)
methadone/heroin
high PSU (3)
buprenorphine/heroin,
low PSU (4)
methadone, moderate
PSU
(5) high PSU (6) high
heroin (7) high
morphine (8) high
methamphetamines
stratified by OST vs
non-OST

Carlson, R. G., Nahhas, R. W., Daniulaityte, R.,
Martins, S. S., Li, L., & Falck, R. (2014). Latent
class analysis of non-opioid dependent illegal
pharmaceutical opioid users in Ohio. Drug and
Alcohol Dependence, 134, 259-266.

US,
respondent
driven
sampling in
Ohio

Prior 6month use

N=390

NMPR, number of
opioid abuse and
dependence criteria, oral
vs non-oral, number of
types of opioids, use of
alcohol or tranquilizers,
reason for opioid use

Dichotomous
with the
exception of
indicator
“reason for
use” (3
nominal
categories)

Australia,
individuals

cannabis, tobacco,
alcohol, amphetamine,

Prior 30day use

Dichotomous

Classes not given
descriptor names,
NW-1 NW-2 NW-3
W-1 W-2 W-3
stratified by race such
that NW=non-white
W=white and
numbers 1-3
indicating most to
least negative patter
of opioid use
(1) wide ranging
substance use (2)
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Betts, K. S., Chan, G., McIlwraith, F., Dietze, P.,
Whittaker, E., Burns, L., & Alati, R. (2016).
Differences in polysubstance use patterns and
drug-related outcomes between people who
inject drugs receiving and not receiving opioid
substitution therapies. Addiction, 111(7), 1214–
1223.

Connor, J. P., Gullo, M. J., Chan, G., Young, R.
M., Hall, W. D., & Feeney, G. F. X. (2013).

Polysubstance Use in Cannabis Users Referred
for Treatment: Drug Use Profiles, Psychiatric
Comorbidity and Cannabis-Related Beliefs.
Frontiers in Psychiatry, 4, 79. doi:
10.3389/fpsyt.2013.00079

referred to
Queensland
Illicit Drug
Diversion
Initiative
N=827
US, Project
AWARE STI
clinics in 9
cities
N= 5,012

ecstasy, heroin,
benzodiazepines

amphetamines, cocaine,
Prior 6MDMA, ketamine, GHB month use
and inhalants, heroin and
pain pills, hallucinogens,
PCP,
tranquilizers/barbiturates,
and marijuana

Ordinal
ranging from
none to daily
(6 intervals)

(1) low use (2) mostly
marijuana (3) sever
club (4) severe street
use stratified by sex
behavior groups (e.g.,
men who have sex
with men)

Fernández-Calderón, F., Blanco-Rodríguez, M.,
Martín-Cazorla, F., Martínez-Téllez, I., SorianoRamón, T., & Bilbao-Acedos, I. (2017). Druginduced deaths in Southern Spain: profiles and
associated characteristics. Journal of Substance
Use, 22(3), 289–294.

Spain,
Toxicology
reports
N=360

methadone,
benzodiazepines, opiates,
cocaine, alcohol,
cannabis, other
substances

Drugs
involved
in death

Dichotomous

(1) methadonebenzodiazepines (2)
cocaine (3)
benzodiazepinescocaine-methadoneopiates (4)
benzodiazepinesalcohol

Fong, C., Matusow, H., Cleland, C. M., &
Rosenblum, A. (2015). Characteristics of NonOpioid Substance Misusers Among Patients
Enrolling in Opioid Treatment Programs: A
Latent Class Analysis. Journal of Addictive
Diseases, 34(2–3), 141–150.

US, 33 state
opioid
treatment
programs
N=19,101

Rx opioids, heroin,
heavy alcohol use (more
than 4 times a day),
marijuana, MDMA,
cocaine or crack, crystal
meth, hallucinogens,
anti-anxiety meds, Rx
sleep meds, and antidepressants

Prior 30day use

Dichotomous

(1) low-use classlargest class (2) nonopioid Rx use (3)
marijuana and/or
cocaine use (4)
polydrug use

Feaster, D. J., Parish, C. L., Gooden, L.,
Matheson, T., Castellon, P. C., Duan, R., …
Metsch, L. R. (2016). Substance Use and
STI Acquisition: Secondary Analysis from
the AWARE Study. Drug and Alcohol
Dependence, 169, 171–179.

cannabis alcohol and
tobacco (3) cannabis
and alcohol
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Gjersing, L., & Bretteville‐Jensen, A. L. (2018).
Patterns of substance use and mortality risk in a
cohort of ‘hard-to-reach’ polysubstance users.
Addiction, 113(4), 729–739.

Norway,
seven cities
street
recruited or
through harm
reduction
services
N=884

heroin, other opioids, Rx
drugs (opioids,
stimulants,
benzodiazepines),
amphetamine, cocaine,
alcohol and cannabis in 4
weeks previous
route of administration

Previous
4 weeks

Ordinal from
no use to
more than 4
times a week
(3 intervals)

Stratified by OST,
OST: (1) frequent
methadone users (2)
frequent
buprenorphine uses
(3) OST heroin
injectors
Non-OST: (1) PSU
injectors (2) frequent
heroin injectors (3)
low frequent injectors

Green, T. C., Black, R., Serrano, J. M. G.,
Budman, S. H., & Butler, S. F. (2011).
Typologies of Prescription Opioid Use in a
Large Sample of Adults Assessed for Substance
Abuse Treatment. PLOS ONE, 6(11), e27244.
doi: 10.1371/journal.pone.0027244

US,
assessments
from
Addiction
Severity
IndexMultimedia
Version
respondents
N=26,314
US, Baltimore
NEURO-HIV
study
N=552

NMPR of long acting Rx
opioid, NMPR of short
acting, use by nonmedical route, illicit
source, chronic health
problem, takes Rx for
medical problem

Prior 30day use

Dichotomous

(1) use as prescribed
(2) prescribed
misusers (3)
medically health
abusers (4) illicit
users

alcohol, cigarettes,
injecting speedball,
injecting heroin, snorting
heroin, injecting cocaine,
smoking crack, smoking
pot

Prior 30day use

Dichotomous

(1) Crack/Nasal
Heroin users (2) PSU
(3) Heroin injectors

Australia,
2010 National
Drug Strategy

alcohol, tobacco,
marijuana, ecstasy,
tranquilizers, cocaine,
hallucinogens,

Prior year
use

Dichotomous

(1) alcohol only (2)
alcohol and tobacco
(3) marijuana, ecstasy
and another licit drug

Harrell, P. T., Mancha, B. E., Petras, H., Trenz,
R. C., & Latimer, W. W. (2012). Latent classes
of heroin and cocaine users predict unique
HIV/HCV risk factors. Drug and Alcohol
Dependence, 122(3), 220–227.

Kelly, A. B., Chan, G. C. K., White, A.,
Saunders, J. B., Baker, P. J., & Connor, J. P.
(2014). Is there any evidence of changes in
patterns of concurrent drug use among young

Australians 18–29years between 2007 and 2010?
Addictive Behaviors, 39(8), 1249–1252.

Household
Survey
N=3,836
US, Baltimore
SHIELD
study
N=1,061

methamphetamine, pain
killers
drank alcohol, smoked
pot, IDU heroin, IDU
speedball, IDU cocaine,
snort heroin, snort
cocaine, smoked crack

Prior 6month use

Dichotomous

(1) heroin injecting
(2) polydrug and
polyroute (3) heroin
and cocaine IDU (4)
heroin snorting (5)
crack smoking

Meacham, M. C., Rudolph, A.E., Strathdee S.A.,
Rusch, M.L., Brouwer, K.C., Patterson, T.L.,
Vera, A., Rangel, G., Roesch, S.C. (2015).
Polydrug use and HIV risk among people who
inject heroin in Tijuana, Mexico: A latent class
analysis. Substance Use & Misuse 50(10), 13511359.
Melendez-Torres, G. J., Bourne, A., Hickson, F.,
Reid, D., & Weatherburn, P. (2018). Correlates
and subgroups of injecting drug use in UK gay
and bisexual men: Findings from the 2014 Gay
Men’s Sex Survey. Drug and Alcohol
Dependence, 187, 292–295.

Mexico, IDU
in Tijuana
N=1,025

cocaine IDU, cocaine
smoking or snorting,
methamphetamine IDU,
methamphetamine
smoking or snorting

Prior 6month use

Dichotomous

(1) predominately
heroin (2)
methamphetamine
heroin (3)
methamphetamine
cocaine heroin

United
Kingdom,
2014 Gay
Men’s Sex
Survey
N=16,464

IDU use of
amphetamine, crystal
meth, heroin,
mephedrone, GHB, and
ketamine

Prior year
use

Dichotomous

(1) chemsex IDUcrystal meth and
mephedrone (2)
opiate IDU- heroin
(3) eclectic IDU- high
IDU of all drugs

Morley, K. I., Lynskey, M. T., Moran, P.,
Borschmann, R., & Winstock, A. R. (2015).
Polysubstance use, mental health and high-risk
behaviours: Results from the 2012 Global Drug
Survey. Drug & Alcohol Review, 34(4), 427–
437.

UK, Australia,
and US
Global Drug
Survey
N=22,289

cannabis, ecstasy,
cocaine, stimulants,
nitrous, ketamine,
benzodiazepines,
opioids- NMPR

Prior 30day use

Dichotomous

(1) non-PSU (2)
cannabis and ecstasy
(3) illicit only (4)
ecstasy and cocaine
(5) cannabis and
medications (6) all
substances

Kuramoto, S. J., Bohnert, A. S. B., & Latkin, C.
A. (2011). Understanding subtypes of inner-city
drug users with a latent class approach. Drug
and Alcohol Dependence, 118(2), 237–243.

use (4) extended
concurrent drug use
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US, NYC
phone survey
with HIV
positive adults
50 and older
N=557

alcohol, marijuana,
cocaine, opiates,
poppers, other drugs
(amphetamines, PCP,
sedatives, solvents)

Prior 30day use

Continuous

(1) exclusive alcohol
use (2) alcohol and
marijuana use (3)
alcohol and
cocaine/crack use (4)
multiple substance
use

Patra, J., Fischer, B., Maksimowska, S., &
Rehm, J. (2009). Profiling poly-substance use
typologies in a multi-site cohort of illicit opioid
and other drug users in Canada-a latent class
analysis. Addiction Research & Theory, 17(2),
168–185.

Canada,
multi-site
cohort study
of illicit
opioid and
other drug
users known
as OPICAN
N=582

alcohol, cannabis,
Demerol, Dialudid,
heroin, methadone from
street, morphine,
Oxycontin, Percocet,
Talwin/Ritalin, Tylenol 3
or 4, cocaine, crack,
benzodiazepines,
IDU

Prior 30day use

Dichotomous

(1) Rx opioids and
cocaine use injectors
(2) Rx opioids noninjectors (3) cocaine
and crack injectors
(4) Rx opioid and
crack non-injectors
(5) nonuse (6) heroin
and crack use
injectors (7) intensive
PSU injectors (8)
alcohol use noninjectors

Quek, L.-H., Chan, G. C. K., White, A., Connor,
J. P., Baker, P. J., Saunders, J. B., & Kelly, A. B.
(2013). Concurrent and Simultaneous Polydrug
Use: Latent Class Analysis of an Australian
Nationally Representative Sample of Young
Adults. Frontiers in Public Health, 1, 61. doi:
10.3389/fpubh.2013.00061

Australia,
2007 National
Drug Strategy
Household
Survey
N=3,011

alcohol, tobacco,
cannabis, ecstasy,
methamphetamine, painkiller,
tranquilizers/sedatives,
cocaine, hallucinogens

Prior year
use

Dichotomous

(1) Alcohol only (2)
Alcohol and tobacco
(3) Cannabis, ecstasy,
and licit drug use (4)
Cannabis,
amphetamine
derivatives, and licit
drug use (5) Sedative
and alcohol use
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Parsons, J. T., Starks, T. J., Millar, B. M.,
Boonrai, K., & Marcotte, D. (2014). Patterns of
substance use among HIV-positive adults over
50: implications for treatment and medication
adherence. Drug and Alcohol Dependence, 139,
33–40.

US, NYC
Club Drugs
and Health
Project
N=400
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CHAPTER 2. HETEROGENOUS OPIOID USE AMONG JUSTICE-INVOLVED INDIVIDUALS: A
LATENT PROFILE ANALYSIS OF POLYSUBSTANCE OPIOID USE (PAPER 1)
2.1

Introduction
Opioid use has reached epidemic levels, impacting individuals as well as criminal justice

and healthcare systems nationwide. Opioid injection drug use (IDU) is increasingly problematic
with overdose mortalities and public health risks such as the hepatitis C virus (HCV) and human
immunodeficiency virus (HIV) increasing as a result (Van Handel et al., 2016). The majority of
opioid related overdoses are due to polysubstance use, which includes the co-use of opioids with
other drugs in a given timeframe (Ruhm, 2017).
Polysubstance use (PSU) refers to the patterns of diverse drug involvement when
substances are used in the same time frame. PSU patterns can be simultaneous (i.e., substances
taken at the same time), sequential (i.e., one substance followed by another), or in regular
intervals (i.e., daily/weekly patterns of use). PSU is widespread, as nearly all individuals who use
drugs do not restrict their substance use to one substance (Darke & Hall, 1995; Martinotti et al.,
2009). Individuals who engage in PSU tend to be younger, with lower levels of education, and
more extensive criminal histories (Darke & Hall, 1995; Martinotti et al., 2009). PSU is inherently
risky, as it is shown to increase likelihood of both fatal and non-fatal overdose (BrettevilleJensen, Lillehagen, Gjersing, & Andreas, 2015; Darke, 2014; Darke, Williamson, Ross, &
Teesson, 2005; Jones et al., 2012) and HIV/HCV transmission risk through IDU practices
(Harrell et al., 2012; Trenz et al., 2012; Wu et al., 2011).
2.1.1

PSU as Inherently Risky
The use of two or more substances greatly increases the risk of overdose. Among

individuals who use opioids nearly one-third of fatal overdoses involve PSU (Mattson, 2018). In
2016, nearly 80% of synthetic-opioid deaths (e.g., fentanyl) involved another substance such as
alcohol, another opioid, cocaine, or benzodiazepines (Jones, Einstein, & Compton, 2018). Post-
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release from prison, individuals are at increased risk of overdose (Binswanger et al., 2007). A
recent study found PSU prevalent in 56% of overdose deaths among formerly incarcerated
individuals, with opioid and cocaine PSU as the most common pattern (Binswanger et al., 2013).
Polysubstance opioid use is also associated with increased risk for non-fatal overdose (Betts et al.,
2016; Roth et al., 2015).
Additional research has found an increased prevalence of IDU among PSU populations
(Betts et al., 2015; Bretteville-Jensen et al., 2015). Further, distinct PSU patterns are significantly
associated with increased HIV and HCV serostatus and risk factors. Individuals who co-use crack
cocaine with nasal use of heroin were more likely to have HCV compared to individuals who
only injected heroin (Harrell et al., 2012). Additionally, HIV/HCV risk behaviors such as syringe
sharing may be more prevalent among PSU populations (Harrell et al., 2012; Meacham et al.,
2015).
In addition to greater risk and symptomology, PSU complicates treatment. For example,
in a sample of individuals entering treatment for heroin dependence, persistent cocaine use during
treatment was associated with increased likelihood of return to heroin use (Williamson, Darke,
Ross, & Teesson, 2006). Individuals with ongoing cocaine use during heroin treatment were also
more likely to report criminal activity and imprisonment (Williamson et al., 2006). In a sample of
methadone program patients, 61% reported increased or resumed misuse of benzodiazepines after
entering treatment (Chen et al., 2011). This study also found that a majority of treatment patients
were interested in treatment for benzodiazepine misuse, indicating that current treatment
modalities may be overly focused on a primary substance of use and may miss important
intervention opportunities.
2.1.2

Latent Modeling Techniques
Prior research has revealed that individuals who use opioids also use a variety of other

substances (Betts et al., 2016; Patra, Fischer, Maksimowska, & Rehm, 2009; Wu, Woody, Yang,
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& Blazer, 2010). Specifically, previous studies have identified opioid use in combination with
alcohol, benzodiazepines, cocaine, marijuana, and amphetamines (Fong et al., 2015; Gjersing &
Bretteville‐Jensen, 2018; Kuramoto et al., 2011; Meacham et al., 2015; Wu, Woody, Yang, &
Blazer, 2010). There are likely distinct preferences and reasons for each PSU pattern. For
example, regular co-use of benzodiazepines and opioids is common with benzodiazepines
involved in 51% of prescription opiate overdoses (Mattson, 2018). Regular interval use of
benzodiazepines with opioids may be motivated by the reinforcing effects by which
benzodiazepines amplify opioid intoxication (Chen et al., 2011; Jones et al., 2012).
Previous research of opioid use tends to focus on a sole substance of
misuse/abuse/dependence despite evidence that the majority of individuals meet criteria for more
than one substance use disorder (Anglin & Hser, 1991; Agrawal, Lynskey, Madden, Bucholz, &
Heath, 2007). To consider the heterogeneity of PSU populations, researchers have advocated for
the use of latent class analysis (Agrawal et al., 2007; Schwartz, Wetzler, Swanson, & Sung,
2010). Latent class analysis, a form of cluster analysis, is considered a person-centered approach
in that it focuses on the relationships between heterogenous groups of individuals to group
individuals into similar categories, known as classes (Collins & Lanza, 2010). Latent class
analysis is preferable to previous deductive, variable-centered approaches as it allows for
consideration of the diverse and multi-dimensional patterns of drug use (Collins & Lanza, 2010;
Monga et al., 2007).
A number of studies have used latent class analysis to explore heterogeneity of substance
use patterns among general populations, with less research focusing specifically on opioid PSU
patterns (e.g., Fong et al., 2015; Gjersing & Bretteville‐Jensen, 2018; Meacham et al., 2015; Wu
et al., 2010). Previous research has utilized dichotomous latent class indicators, which more
accurately capture regular interval PSU in the time-period analyzed. For example, Monga and
colleagues (2007) explore substances individuals report using in the prior 30-days. A 30-day time
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frame is commonly used in previous studies (e.g., Fong et al., 2015; Harrell et al., 2012; Patra,
Fischer, Maksimowska, & Rehm, 2009). Other research utilizes ordinal categories of substance
use (e.g., Betts et al., 2015; Carlson et al., 2014; Gjersing & Bretteville‐Jensen, 2018). Only one
known study used 30-day continuous indicators of substance use (Parsons et al., 2014), and the
current research advocates further examination of PSU patterns using continuous indicators as
necessary in order to provide more detailed insights to PSU patterns.
Among studies examining substance use patterns, none have examined patterns explicitly
among a justice-involved sample. Some research examines justice-involvement as an independent
variable, and has found more extensive PSU patterns associated with higher justice-involvement
(Betts et al., 2016; Fernández-Calderón et al., 2015; Green, Black, Serrano, Budman, & Butler,
2011).
Compared to the general public, justice-involved populations have more severe drug use
histories (Mumola & Karberg, 2006). Studies have found 30-74% of currently incarcerated
individuals report using more than one substance prior to incarceration (Kubiak, 2004; Lo &
Stephens, 2000) and one study found 10% of users met criteria for substance use disorder for two
or more substances (Lo & Stephens, 2000). This indicates justice-involved populations have
higher rates of PSU, and explicit examination of this population’s PSU patterns are necessary in
order to provide supportive treatment during incarceration as well as reentry and post-release
treatment services.
2.1.3

Current Research
Justice-involved populations have complex histories which place them at a

disproportionate risk for PSU. Criminal involvement is highest during periods of active use
(Fisher et al., 2014), making justice system involvement a key intervention point. Individuals
with PSU are more likely to be arrested or recidivate upon release (Fisher et al., 2014; Hakansson
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et al., 2011). Given the current opioid epidemic, and that known estimates of PSU among justiceinvolved persons explore only prevalence and not patterns, the current research describes the PSU
patterns of users of opioids prior to their entrance to a prison and jail-based substance abuse
treatment program. Persons who use opioids are not a homogenous group and assuming that all
individuals have similar substance-using patterns undermines the potential for successful
treatment and reentry outcomes. In this study, a latent profile analysis (LPA) of justice-involved
persons who report use of opioids with other substances is explored. LPA is a form of latent class
analysis which uses continuous indicators instead of dichotomous or ordinal indicators. The
current research expands previous research by providing the unique contributions of (1)
examination of PSU patterns among a justice-involved population, and (2) use of continuous
indicators and LPA to reveal detailed insights to PSU patterns.

2.2
2.2.1

Methods
Sample
Data from the current study were collected from the Criminal Justice Kentucky

Treatment Outcome Study (CJKTOS). The study is on-going since 2005 with the collaboration of
the Kentucky Department of Corrections (DOC) and the University of Kentucky Center on Drug
and Alcohol Research (UK CDAR). Individuals entering KY DOC jails, prisons, and community
corrections in need of substance abuse treatment are eligible to participate in a substance abuse
program (SAP), which follows a therapeutic community model (De Leon, 2000). Baseline
assessments were conducted by trained DOC staff using computer assisted personal interview
(CAPI) software within the first two weeks individuals entered SAP. Consent to baseline
assessment is part of DOC consent to treatment. A federal certificate of confidentiality was
obtained.
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The current analyses are limited to the three most recent cohorts: 2015, 2016, and 2017
(n=17,203). Further, the sample was limited to include only individuals in prison or jail-based
SAP (n=13,490). Finally, individuals in current analysis must have reported use of an opioid
(e.g., heroin, illicit suboxone, non-prescribed opiates) in the 12-months (n=7,837) prior to
incarceration and had to have reported using more than one substance on a given day in the
month prior to incarceration, resulting in a final sample size of 6,569. Individuals were
incarcerated an average of 1.70 years before entering SAP and receiving their baseline
assessment.
2.2.2

Variables
2.2.2.1

Latent Profile Indicators

The baseline assessment contained a variety of demographic, criminal history, mental and
physical health, and substance use questions. Individuals were first asked if they used a substance
in the 12-months prior to their incarceration. If an individual indicated they used a substance, they
were then asked about use of the substance in the 30-days prior to incarceration (i.e., number of
days used). Following previous studies and statistical practices (Kuramoto et al., 2011; Monga, et
al., 2007), only 30-day drug use that was engaged by a minimum of 20% of the sample was
included in the current research. This resulted in the exclusion of barbiturates (5.7%),
hallucinogens (7.2%), inhalants (2.9%), non-prescribed methadone (14.8%), and synthetic drugs
(16.8%). Latent profiles were created based on previous 30-day use of alcohol, cocaine,
marijuana, heroin, non-prescribed suboxone, non-prescribed opiates, amphetamines, and
tranquilizers.
2.2.2.2

Sociodemographic

Age and years of education were measured as continuous variables. Gender (1=male) and
race (1=white) were dichotomously measured. The county an individual lived in prior to
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incarceration was coded utilizing a rural-urban coding scheme (Ingram & Franco, 2014) such that
codes 1-3 were coded as 0=urban and 4-6 were 1=rural. Employment (1=unemployed) in the 30days prior to incarceration was measured dichotomously. Additionally, prior 12-month
homelessness was also measured (1=homeless during prior 12-months). Pre-incarceration
financial strain was measured on an 8-item summative scale (α=.87; R:0-8) of economic hardship
adapted from the Survey of Income and Program Participation to include difficulty meeting needs
of food, housing, clothing, and medical care (Beverly, 2001).
2.2.2.3

Physical Health

Individual’s physical health was measured by three variables. A dichotomous variable
measured if individuals reported chronic pain where pain persisting or recurring three months or
longer was coded “1” and no pain or pain not meeting that criteria was coded “0”. Additionally,
HCV status was measured by a question asking if the individual had been told by a doctor that
they have the hepatitis C virus. A continuous variable measuring the number of poor physical
health days in the 30-days prior to incarceration was also included via the question, “Thinking
about your physical health, which includes physical illness and injury, during the 30 days prior to
this incarceration, how many days was your physical health not good?” (R:0-30).
2.2.2.4

Mental Health

Anxiety and depressive symptoms in the 12-months prior to incarceration were measured
using a modified dichotomous version of the Generalized Anxiety Disorder-7 (GAD-7; Spitzer,
Kroenke, Williams, & Löwe, 2006) (α= .97; R:0-7) and the Patient Health Questionnaire-9
(PHQ-9; Spitzer, Kroenke, Williams, & Group, 1999) (α=.94; R: 0-9). Additionally, three
questions measuring stress-related health consequences were examined (Logan & Walker, 2010).
These questions ask if participants (1) used illegal drugs to reduce stress, anxiety, worry or fear;
(2) used alcohol to reduce stress, anxiety, worry or fear; and (3) used prescription drugs to reduce
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stress, anxiety, worry or fear in the week prior to their incarceration. Answers were collapsed so
that individuals reporting response of ‘most of’ or ‘all of the time’ were compared to those
reporting ‘none of’ or ‘some of the time.’ A continuous variable measuring the number of poor
mental health days in the 30-days prior to incarceration was also included via the question,
“Thinking about your mental health, which includes stress, depression and problems with
emotions, during the 30 days prior to this incarceration, how many days was your mental health
not good?” (R: 0-30).
2.2.2.5

Criminal History

A continuous variable measuring self-reported lifetime number of criminal convictions
was included. In addition, a series of dichotomous variables were created to measure prior 12month arrests according to offense type (drug, violent, property). Drug crimes included
trafficking, possession, paraphernalia, and manufacturing charges. Violent crimes included
weapon offenses, robbery, assault, rape, and homicide. Property crimes included shoplifting,
burglary, and arson. There were other crimes that did not fit one of the three categories (e.g.,
receiving stolen property, 5.6%), which were excluded. Individuals could report prior arrests for
more than one type of crime.
2.2.3

Analysis
LPA was utilized to determine the unobserved patterns of the data utilizing the 30-day

reported substance use indicators to form subgroups. A simple model (1-class) was fit first and
classes were then incrementally increased until selection criteria began to decline. Selection
criteria were based on standard fit statistics of Akaike Information Criteria (AIC), Bayesian
Information Criteria (BIC), and likelihood ratio tests. Although AIC and BIC were slightly
improved with a 7-profile solution, the profiles were not parsimonious and did not reach
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separation. A six-profile model was the most parsimonious, homogenous, with separation (see
Table 2.1).
Once the final six-profile model was selected, cross-validation and model convergence
was tested by randomly varying the starting points for the maximum likelihood. A model is
considered identified when classes consistently converge regardless as to maximum likelihood
starting point (Collins & Lanza, 2010). Random iterations and the log likelihood converged to the
same six-factor model selected in 76.2% of tests indicating the six-profile solution was wellfitting and robust.
Individuals were assigned to profiles based on their most likely profile membership.
Profile membership is independent in that individuals cannot belong to more than one profile.
Chi-square tests and ANOVA were used to determine if profiles differed from each other on
associated variables. Multinomial logistic regressions were used to predict profile membership
(i.e., latent profile as outcome variable), adjusted for relevant variables. All analyses were
conducted using the latent class functions in Stata version 15.1.

2.3
2.3.1

Results
Profile Membership
The six-profile model selected appears in Table 2.2, with mean number of days of

substance use in the 30-days prior to incarceration. Profile 1 (P1) representing 9.4% of the sample
was characterized by near daily alcohol use with substantial co-use of marijuana and opiates
about 50% of the month (Primarily Alcohol P1). Profile 2 (P2) was characterized by near-daily
use of heroin and co-use of marijuana and opiates about 40% of the month (Primarily Heroin P2).
The most prevalent profile, with 34.3% of the sample, was characterized by Low PSU (P3).
While use of opiates and marijuana was still substantial, compared to other profiles the Low PSU
P3 did not have any drug use above 20 days per month. Profile 4 (P4), with 16.3% of the sample,
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was characterized by high PSU, particularly of opiates and near daily use of tranquilizers. Co-use
of marijuana and amphetamines was additionally high (High PSU P4), occurring 30-40% of the
days of the month. Profile 5 (P5) was the smallest group with 7.8% of the sample. Individuals in
this profile had daily use of illicit suboxone with substantial co-use of marijuana, opiates, and
amphetamines about 40% of the month (Primarily Suboxone P5). Profile 6 (P6) was characterized
by near daily cocaine use and high co-use of marijuana, opiates, and heroin 50-60% of the month
(Stimulant-Opioid P6).
2.3.2

Characteristics of Sample
Sociodemographic, physical health, mental health, and criminal history information of

the total sample and by latent profile is provided in Table 2.3. The overall study population was
predominantly white males in their 30s with an average of 12 years of education/GED. The
sample was equally split between rural and urban, with the majority (54%) employed prior to
incarceration. Approximately one-third had experienced homelessness in the 12 months prior to
incarceration and reported an average of two sources of financial strain. Twenty-one percent of
the sample reported having HCV, and nearly 30% reported chronic pain. Individuals reported an
average of 7 days of poor physical health and nearly 12 days of poor mental health in the past 30
days. Anxiety and depression scores were mid-range for each scale. The majority of individuals
reported using illegal drugs to cope, less reported use of prescriptions, and even fewer individuals
reported using alcohol to cope. The average person was incarcerated 1.7 years with a history of
10 previous convictions. Drug crimes were the most prevalent offense followed by property
crimes in the 12 months before incarceration.
2.3.3

Sociodemographic Characteristics of Profiles
All variables were significantly different by latent profile as indicated by chi-square and

ANOVA tests. Post-hoc Tukey-Kramer comparisons were performed after ANOVA results
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(p<.05), and relevant results are discussed. Individuals characterized by Primarily Alcohol P1
were significantly older (x̄ =34.22) than all profiles except High PSU P4. Primarily Heroin P2
were on average the youngest (x̄ =31.58), and significantly younger than all profiles other than
Stimulant-Opioid P6. Primarily Suboxone P5 individuals had significantly lower level of
education compared to Primarily Heroin P2, Low PSU P3, and High PSU P4. While all profiles
consisted of mostly males, individuals in Primarily Alcohol P1 had the highest prevalence
(88.7%). The Primarily Suboxone P5 group averaged the highest majority white (68.4%)
compared to the lowest prevalence of Primarily Alcohol P1 (57.3%). Only 27.9% of Primarily
Heroin P2 lived in rural locations prior to incarceration, contrasted with 75.8% of Primarily
Suboxone P5. Individuals included in Primarily Alcohol P1 were most likely to have employment
before incarceration. Homelessness and economic hardship were more common among Primarily
Heroin P2 and Stimulant-Opioid P6 than all other profiles.
2.3.4

Physical and Mental Health Characteristics of Profiles
Primarily Alcohol P1 individuals had the lowest reported HCV prevalence while highest

reported HCV was 26.7% among the Primarily Heroin P2 individuals. Chronic pain was highest
among Primarily Suboxone P5. The Low PSU P3 group reported significantly lower physical and
mental health symptomology (days and depression/anxiety) compared with the Primarily Heroin
P2, High PSU P4, and Stimulant-Opioid P6. Other significant differences were found across
mental and physical health variables when comparing the High PSU P4 group to the Primarily
Suboxone P5.
Primarily Suboxone P5 individuals also had on average higher reports of using
prescriptions and illegal drugs to cope. Reports of using illegal drugs to cope were also high
(80.1%) among Primarily Heroin P2. Unlike the total sample and other profiles, Primarily
Alcohol P1 was most likely to report using alcohol to cope.
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2.3.5

Criminal History Characteristics of Profiles
Individuals characterized by Primarily Alcohol P1 patterns were incarcerated a longer

number of years compared to Primarily Heroin P2, Low PSU P3, and Primarily Suboxone P5.
This group also had higher than average lifetime convictions and violent crimes. The StimulantOpioid P6 group had the highest average number of convictions, with significant differences
observed between this group and Primarily Heroin P2, Low PSU P3, and High PSU P4. The
Stimulant-Opioid P6 profile had the highest average number of arrests for property crimes.
Individuals characterized by Largely Heroin P2 had the lowest amount of reported violent crime
arrests. The Low PSU P3 reported the highest amount of arrests for drug-related crimes.
2.3.6

Multivariate Models
Table 2.4 contains multinomial logistic regression identifying the correlates associated

with profile membership using variables which were associated with latent profiles at the p<.05
level (correlation matrix not shown). The Low PSU P3 group was chosen as the comparison
group so that it could be understood how the higher risk profiles differed (i.e., which
characteristics may be associated with riskier PSU patterns). Compared to Low PSU P3,
individuals were more likely to be classified as Primarily Alcohol P1 if they reported using
alcohol to cope and with increasing number of convictions. Those who reported using
prescription or illegal drugs to cope were less likely to be classified as Primarily Alcohol P1.
Individuals were more likely to be classified as Primarily Heroin P2 if they had lived in
urban areas, used illegal drugs to cope, and had a history of IDU. If individuals had lived in a
rural area and with increasing poor physical health and anxiety symptoms, they were more likely
to be in the High PSU P4 group. Additionally, individuals were more likely to be High PSU P4 if
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they had lower levels of education, reported alcohol and prescription use to cope, injected drugs,
and had a greater number of lifetime convictions.
Individuals with lower levels of education or who lived in rural areas were more likely to
be in the Primarily Suboxone P5 group. With increased anxiety symptoms and histories of using
prescriptions to cope, individuals were more likely to be classified as Primarily Suboxone P5 as
well. Individuals were less likely to be in this profile with decreased depression symptomology or
if they used alcohol to cope. Individuals who were HCV positive were most likely to be classified
as Stimulant-Opioid P6. Individuals were also likely to be classified in Stimulant-Opioid P6 with
lower levels of education, urban living, increasing depression symptoms and a history of using
alcohol to cope. Further histories of IDU, property crimes, and a greater number of convictions
was associated with increased likelihood of being classified by Stimulant-Opioid P6 profile.

2.4

Discussion
The current research is among the first to explore PSU among a sample of justice-

involved persons who use opioids. Specifically, LPA identified six distinct profiles of opioid PSU
in the 30-days prior to incarceration with profiles distinguished by their use of Primarily Alcohol,
Primarily Heroin, Low PSU, High PSU, Primarily Suboxone and Stimulant-Opioid. These
profiles differed in key ways which are relevant to public health and criminal justice systems and
can be used to inform intervention development. Qualitative summaries of differences are
described in Table 2.5.
All profiles in the current research reported co-use of marijuana at least 40% of the
month. The high co-use of marijuana and opioids has been observed among PSU populations
(Monga et al., 2010; Trenz et al., 2012; Wu et al., 2010). In a study of users of opioids in Canada,
marijuana use was 50% or greater among latent classes (Monga et al., 2007). Previous research
demonstrates the role of the endocannabinoid system in opioid use disorder, and the potential for
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marijuana to diminish opioid withdrawal (Bisaga et al., 2015). Considering all profiles reported
substantial use of opioids by study design, it is possible that high marijuana use is related to a
pharmacological desire or need to reduce symptoms of opioid withdrawal.
Individuals classified as Primarily Alcohol P1 were older, reported using alcohol to cope,
with more extensive incarceration histories including a history of violent crimes. Generally, a
curvilinear age to crime relationship exists, such that older individuals become less criminally
involved (Sampson & Laub, 1995). While older, individuals in this profile were only an average
of 34 years old; this remains an age range for which extensive offending occurs, particularly for
alcohol and drug related offenses (Sampson & Laub, 2003). Additionally, alcohol use is a
common correlate of violent crimes (Graham & Livingston, 2011). Given the propensity for
individuals in this profile to report drinking alcohol as a method of coping, appropriate
interventions which introduce effective coping mechanisms are appropriate. It has long been
noted that relapse to alcohol use is likely during stressful experiences among individuals with
limited coping skills (Rohsenow et al., 2001). Providing coping skill training reduces future
alcohol relapse, both when provided alone (Rohsenow et al., 2001) and in conjunction with
pharmacotherapies (O’Malley et al., 1992). While therapeutic communities, a common prisonbased substance program, often require desistance from unhealthy coping mechanisms, there is no
known longitudinal research on the use of these coping skills post-release including the effects of
training on post-release substance use. However, research indicates individuals who enroll in
therapeutic community aftercare are most likely to remain substance-free long-term (Inciardi,
Martin, & Butzin, 2004), supporting the idea that assistance with coping skills in presence of
relapse stimuli (e.g., alcohol) would be most effective (Rohsenow et al., 2001).
Those classified as Primarily Heroin P2 were younger, more likely to be HCV positive,
lived in urban areas, reported IDU, and the use of illegal drugs to cope. Considering the findings
on coping, the previous recommendations regarding coping skills would apply for this population
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as well. The young age, HCV probability, and IDU practices of this population when combined
with consideration that substance use is a chronic relapsing disorder, indicates that harm
reduction resources and pharmacotherapies should be made readily available. Opioid substitution
therapies (OST) remain a safe and cost-effective method to treat individuals with an opioid use
disorder (Volkow, Frieden, Hyde, & Cha, 2014), but are underutilized in justice settings
(Friedmann et al., 2012). Owing to a focus on ‘drug-free’ as a ‘true recovery’ among treatment
centers (Friedmann & Suzuki, 2017), it is highly unlikely that discussion of harm reduction
resources occurs. It is critical that individuals such as those identified in the Primarily Heroin P2
profile are provided with safe reentry resources and appropriate medications for treatment in
addition to psychosocial services.
Individuals in the Low PSU P3 were characterized by markedly lower PSU, but still
reported frequent use (i.e., 30% or more of month) of marijuana, opiates, and amphetamines.
Thus while their PSU patterns were ‘low’ when compared to the more severe patterns of their
justice-involved peers, they are still quite high compared to more general populations (e.g.,
Parsons et al., 2014). Individuals classified by this PSU pattern had higher than average education
and the lowest prevalence of IDU. While they are not as high-risk as other individuals, their risk
remains substantial. As no outstanding characteristics arose from this group, it is possible that
standard correctional treatment modalities would assist in reducing their substance use. Due to the
elevated use of opiates, individuals in this profile would benefit from screening for opioid use
disorder and potential OST, when applicable.
The High PSU P4 profile represents a high-risk group in need of substantial intervention.
While previous latent class analyses have found a PSU class with comparably higher PSU
patterns from other classes (Fong et al., 2015; Harrell et al., 2012; Kelly et al., 2014; Kuramoto et
al., 2011; Morley et al., 2015; Parsons et al., 2014; Patra et al., 2009; Wu et al., 2010), similar to
those observed in the current High PSU profile, the type of substances used vary based on study
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inclusion. Instead it remains notable that among most samples of substance users, a proportion
engage in more heterogenous patterns of frequent use. Additionally, since previous research
utilized dichotomous and ordinal measures of substance use, it is difficult to make comparisons
with regards to the patterns of PSU observed in the current sample. Despite these differences,
research has found that those latent classes with more diverse drug involvement are at risk for
poor outcomes (Connor et al., 2013; Quek et al., 2013; Wu et al., 2011).
This profile’s association with chronic pain, poor physical and mental health, and
reported illicit prescription drug use to cope should be considered. Further, assessment and
treatment of physical and mental health are imperative. Appropriate intervention for coping skills
should be implemented. With caution, as causality of variables cannot be accounted, this profile
appears to exhibit characteristics indicative of a self-medication model of substance use. It is
important to note that individuals need not meet criteria of a disorder (e.g., depression) for selfmedication to occur (Mariani, Khantzian, & Levin, 2014). Rather, the perceived pain and
psychological distress lead an individual to focus on the relief and control of pain (physical and
psychological) (Khantzian, 2003). Further, the patterns of an individual’s self-medication are
crucial in understanding which appropriate psychological and psychopharmacological treatment
approaches are most appropriate (Khantzian, 2003; Mariani et al., 2014).
A study by Betts and colleagues (2015) found that individuals with certain PSU patterns
were at increased risk of overdose only when psychological distress was also found. That is,
something about the nature or way that distressed individuals consume multiple substances places
them at increased risk for nonfatal overdose (Betts et al., 2015). Since co-consumption of
tranquilizers (e.g., benzodiazepines) with opioids already places individuals at greater risk of
overdose, the individuals in the High PSU P4 are at extreme risk of negative outcomes without
appropriate targeted interventions.
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Individuals in the Primarily Suboxone P5 group represent a unique profile, which has not
previously been found in the literature. Individuals in this profile reported near daily use of illicit
suboxone, with co-use of marijuana, opiates, and amphetamines. These individuals were more
likely to have lived in rural locations with reported lower levels of education. The rurality of this
profile is important to consider. Rural areas of Kentucky have limited methadone and other
treatment access (Bunting et al., 2018). Some evidence suggests that overprescribing or ‘doctor
shopping’ contributes to the diversion of Suboxone (Furst, 2014). These are the same
mechanisms mentioned in rural areas when examining diversion of prescription opiates
(Leukefeld, Walker, Havens, Leedham, & Tolbert, 2007), indicating the unique importance of
rurality for this finding and the potential that indiscriminate Suboxone prescribing may be filling
a void left by the crackdown on pain clinics. Again, motivations for use are unknown among this
sample, but it is posited that these individuals represent a new form of the self-medication
hypothesis, specific to the opioid epidemic. Research has explored motivations for illicit
buprenorphine use (Yokell, Zaller, Green, & Rich, 2011) and while some studies report diverted
use for euphoric effects, substantial evidence exists to support that illicit use can be motivated by
therapeutic purposes (i.e., self-treatment of opioid withdrawal symptoms) (Bazazi, Yokell, Fu,
Rich, & Zaller, 2011; Hakansson, Medvedeo, Andersson, & Berglund, 2007; Schuman-Olivier et
al., 2010). However, this should not assume that illicit use is without consequences. Although the
use of illicit Suboxone may be safer than heroin use, due to the unknown purity and adulterants in
heroin, its use remains a risk for overdose particularly when PSU or IDU is involved (BrettevilleJensen et al., 2015; Yokell et al., 2011). This profile provides a crucial intervention point for
access to prescribed Suboxone and the addition of psychosocial counseling under the care of a
licensed-buprenorphine healthcare provider during the captive moment of incarceration.
Lastly, individuals in the Stimulant-Opioid P6 were found to have lower education, a
greater number of depressive symptoms, more likely to be HCV positive, and a more pronounced
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history of property crimes. This profile has been found in other research of PSU patterns (Harrell
et al., 2012; Kuramoto et al., 2011; Meacham et al., 2015; Monga et al., 2007; Patra et al., 2009;
Roy, Richer, Arruda, Vandermeerschen, & Bruneau, 2013). The use of stimulants with opioids is
a more common PSU pattern, owing to more pleasurable effects or the use of stimulants to reduce
opioid withdrawal symptoms (Leri et al., 2003). This repeated finding demonstrates that at the
time of assessment, treatment providers have the potential to classify individuals PSU patterns.
While future research is needed to determine if the current findings replicate in other justice
settings, at this point substantial evidence exists that PSU of stimulants and opioids occurs.
Consideration of separate and unique treatment for this population could be warranted. As
research finds distinct motivations for stimulant-opioid co-use (e.g., euphoric effects, stave
withdrawal), further understanding of the motivation of co-use among this population would be
beneficial. For example, individuals who co-use stimulants to postpone withdrawal might benefit
from OST.
The current research was descriptive in nature, but the intended goal is to provide critical
information for criminal justice and public health officials. While PSU is risky and poor
outcomes are increased among general populations, the risks for justice-involved populations are
unique. Justice-involved persons leave prisons and jails after periods of prolonged substance
abstinence. The risk of overdose is 129 times greater upon reentry (Binswanger et al., 2007).
Tailoring intervention efforts during incarceration has the potential to reduce risky PSU patterns
post-release, reduce future criminal justice involvement, and save lives. Recognizing that opioid
use, and substance use in general, is heterogenous and diverse is crucial to successful treatment
and intervention success.
2.4.1

Recommendations for Future Research
This research was among the first to utilize LPA with 30-day indicators of substance use

as opposed to dichotomous and ordinal substance use variables in latent class analysis. The only
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other known study to explore PSU using continuous latent variable is Parsons and colleagues
(2014), which was a limited sample of HIV positive adults over the age of 50 in New York City.
While several studies have examined PSU patterns of opioids (Fong et al., 2015; Gjersing &
Bretteville‐Jensen, 2018; Kuramoto et al., 2011; Meacham et al., 2015; Wu et al., 2010), there is a
need for future research to utilize continuous indicators and LPA so that more nuanced
understandings of PSU may occur. Further, future research should include indicators that this
current study did not measure- such as method of use (i.e., injection, snort, smoke, swallow) and
inclusion of commonly known simultaneous PSU substances (e.g., speedball). Improved
polysubstance use measures that capture simultaneous and sequential use, as well as studies that
explore motivations for PSU are needed.
Whenever available, associated variables measured the 30-days prior to incarceration so
as to be consistent with the 30-day LPA indicators. However, this was not always possible, due to
measurement design and leaves uncertain the causality of results. Further, the current research
examined only the phenomena of purposeful PSU- that is unknown PSU was not considered.
Unintentional or unknown PSU is increasing due to synthetic opioid analogs adulterating other
substances (Krieger et al., 2018). While the risks of unintentional PSU are great, the goal of the
current research was to understand purposeful PSU in order to examine risk taking behaviors that
are employed with active agency. Given the prominence of synthetic opioids, it is likely that
individuals in the current sample- particularly those consuming heroin- unintentionally ingested
other substances as well. Future research of PSU should consider the juxtaposition of intentional
versus unintentional PSU behaviors. Finally, all behaviors were self-reported in a criminal justice
setting. While extensive research has indicated that self-report measures of substance use are
likely legitimate (Darke, 1998), there is the possibility of inaccurate details due to lack of rapport,
bias, or recall.
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The current study was the first known study to explore PSU in a justice-involved sample
and while several previous studies likely have samples consisting of those with justiceinvolvement, the current research explicitly considered this as integral to the research. Future
studies should examine PSU among justice-involved populations, particularly at the point of
introduction to the justice system since substance use is likely elevated at this time point. Future
studies of PSU should also consider measuring previous justice involvement, and this variable as
a possible stratification of groups for future latent class/profile analyses, as well as post-release
patterns in latent transition analysis.
2.4.2

Conclusions
The current research is the first to examine the polysubstance profiles of justice-involved

users of opioids. There were distinct profiles of opioid use, highlighting the diverse substance
involvement of justice-involved populations. The current sample differed in these patterns of use
by sociodemographic, physical health, mental health, and criminal history. Justice involvement
provides a crucial point for intervention and criminal justice agencies should consider treatment
efforts focused on unique patterns of substance use. Future research of the diverse substance
patterns of justice-involved individuals, to include longitudinal research, is crucial to curbing the
opioid epidemic.
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Table 2.1 Fit statistics for a latent profile analysis of polysubstance opioid use
Number of
Profiles

Loglikelihood

Degrees of
freedom

1
-204822.7
16
2
-201122.9
25
3
-200226.8
34
4
-199959.5
43
5
-197275.0
52
6
-196888.3
61
7
-196519.7
70
Note: Latent profile selected shown in bold.

Akaike
Information
Criteria
409677.5
402295.7
400521.7
400005.1
394654.1
393898.7
393179.4
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Bayesian
Information
Criteria
409786.1
402465.5
400752.6
400297.1
395007.2
394312.9
393654.7

Table 2.2 Latent profile conditional means for polysubstance opioid use

Descriptive
profile
abbreviation
Latent Profile
indicators:
Prior 30- day
use
Alcohol
Cocaine
Marijuana
Heroin
Suboxone
Opiates
Amphetamin
es
Tranquilizers
Profile
Prevalence

Profile 1
(N= 618)
Primarily
Alcohol
P1

Profile 2
(N=1,247)
Primarily
Heroin P2

Profile 3
(N=2,255)
Low PSU
P3

Profile 4
(N=1,070)
High PSU
P4

Profile 5
(N=513)
Primarily
Suboxon
e P5

Profile 6
(N=866)
Stimulant
-Opioid
P6

28.03
1.28
14.65
1.20
4.93
14.30
9.38

3.94
1.73
11.53
28.88
4.56
12.94
9.18

2.43
0.73
12.11
1.37
1.63
14.21
10.77

7.51
1.20
16.47
7.47
9.46
20.80
12.04

1.96
0.82
12.18
1.30
29.03
12.28
12.73

10.22
27.38
17.99
14.93
8.60
18.18
11.18

2.78

2.52

1.78

28.66

2.29

11.01

9.41%

18.98%

34.33%

16.29%

7.81%

13.18%
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Table 2.3 Characteristics of poly-opioid use in a criminal justice sample (N=6,569)
StimulantOpioid P6

Primarily
Suboxone
P5

High PSU
P4

Low PSU
P3

Primarily
Heroin P2

Education
Level
Male
White
Rural
Unemployed
Homeless
Economic
Hardship (R:08)
Physical Health
HCV positive
Chronic Pain
Number of
poor physical
health days in
past month
Mental Health
Anxiety (R:07)
Depression
(R:0-9)
Number of
poor mental
health days in
past month
Use alcohol to
cope
Use Rx drugs
to cope
Use illegal
drugs to cope
Criminal History
# of years
incarcerated
Lifetime
number of
convictions

Primarily
Alcohol
P1

Total
Sample
Sociodemographic
Age

32.72
(8.07)
11.91
(2.13)
81.88
60.71
50.18
45.71
28.01
1.93
(2.48)

34.22
(8.88)
11.88
(2.10)
88.67
57.28
54.05
38.67
27.67
1.88
(2.45)

31.58
(7.17)
12.02
(1.98)
80.27
64.96
27.99
46.75
36.09
2.30
(2.69)

32.87
(8.24)
12.02
(2.10)
81.24
59.02
52.90
45.28
23.55
1.69
(2.29)

33.28
(8.47)
11.77
(2.30)
79.44
58.41
62.06
48.41
23.55
1.82
(2.37)

32.12
(7.27)
11.63
(2.13)
83.63
68.42
75.83
46.78
23.0
1.83
(2.39)

32.52
(7.89)
11.80
(2.20)
83.03
59.70
42.38
46.42
36.72
2.27
(2.71)

20.99
29.12
7.23
(11.92)

13.43
28.48
6.14
(11.40)

26.78
26.30
7.73
(12.23)

17.34
29.50
6.37
(11.29)

21.12
36.07
9.05
(12.83)

24.37
25.15
6.26
(11.16)

25.40
27.60
7.85
(12.35)

3.48
(3.21)
4.30
(3.62)
11.74
(13.70)

3.52
(3.23)
4.29
(3.65)
11.91
(13.89)

3.48
(3.21)
4.46
(3.63)
11.99
(13.89)

3.13
(3.17)
3.83
(3.60)
10.53
(13.23)

3.96
(3.19)
4.84
(3.59)
13.95
(13.99)

3.34
(3.23)
3.76
(3.60)
10.24
(13.19)

3.90
(3.18)
5.00
(3.46)
12.59
(14.00)

27.46

66.99

19.09

17.87

31.78

15.20

38.22

50.66

48.87

42.82

43.41

72.99

54.97

51.96

71.75

64.40

80.11

63.73

80.56

66.08

78.29

1.70
(2.29)
10.10
(14.29)

2.02
(2.68)
11.48
(16.23)

1.45
(2.17)
10.07
(12.63)

1.68
(2.04)
8.69
(12.55)

1.87
(2.79)
11.07
(15.99)

1.44
(1.40)
9.20
(14.23)

1.81
(2.48)
12.19
(16.67)
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Table 2.3 (continued)
StimulantOpioid P6

Primarily
Suboxone
P5

High PSU
P4

Low PSU
P3

Primarily
Heroin P2

Primarily
Alcohol
P1

Total
Sample

Arrest for
18.44
17.31
20.45 16.19 17.01 18.52
23.90
property crimes
past 12-months
Arrest for violent
9.79
12.62
6.50
10.07 10.84 7.02
12.12
crimes past 12months
Arrest for drug
29.02
23.14
28.71 31.71 28.97 26.71
28.06
crimes past 12months
Notes: Percentages and means (SD) presented. All variables significant at p<.001 level with
exception of unemployment which is significant at the level of p<.01
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Table 2.4 Estimated significant relative risk ratios and 95% confidence intervals between
relevant variables and poly-opioid use in a criminal justice sample compared to Low
PSU(P3)

0.93***
(0.88-0.97)
2.50***
(2.00-3.13)

Unemployed
HCV positive

0.94**
(0.91-0.98)
0.63***
(0.54-0.75)
1.27*
(1.03-1.56)

Number of
poor physical
health days in
past month
Anxiety

1.01*
(1.00-1.01)

1.03*
(1.00-1.06)

Depression
Use alcohol
to cope

Stimulant
-Opioid
P6

High PSU
P4

0.31***
(0.27-0.37)

0.94**
(0.91-0.98)
1.29***
(1.11-1.51)

Primarily
Suboxone
P5

Primarily
Heroin P2

Primarily
Alcohol
P1

Education
level
Rural

14.91***
(11.7018.99)
0.70**
(0.56-0.88)
0.42***
(0.33-0.54)

1.44***
(1.20-1.73)

1.04*
(1.00-1.08)
0.96*
(0.93-0.99)
0.72*
(0.55-0.96)

Use Rx drugs
0.74***
2.73***
1.66***
to cope
(0.63-0.88) (2.27-3.29) (1.31-2.10)
Use illegal
2.15***
drugs to cope
(1.77-2.60)
Injection
4.11***
1.32***
1.85***
drug use
(3.42-4.96) (1.12-1.56) (1.47-2.33)
Property
crimes
Lifetime
1.01***
1.01***
number of
(1.01-1.02)
(1.00-1.02)
convictions
Note: Significance indicated by *p<.05, **p<.01, ***p<.001
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1.05**
(1.02-1.08)
2.50***
(2.07-3.03)

1.38**
(1.12-1.71)
1.42***
(1.19-1.71)
1.48***
(1.22-1.81)
1.01***
(1.01-1.02)

Table 2.5 Comparison summary of latent profiles
Profile
1

Profile Description
Primarily Alcohol

2

Primarily Heroin

3

Low PSU

4

High PSU

5

Primarily Suboxone

6

Stimulant-Opioid

Uniqueness of profile
Older
Use alcohol to cope
More multiracial
Incarcerated longest
Youngest
HCV +
Urban
IDU
Use illegal drugs to cope
Higher education
Lowest IDU prevalence
Chronic pain
Poor physical and mental
health
Use Rx drugs to cope
Rural
Less education
White
Less education
Urban
HCV+
Greater # of depressive
symptoms
Property crimes
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CHAPTER 3. RETURN TO SUBSTANCE USE: A POST-RELEASE EXAMINATION OF
POLYSUBSTANCE USE (PAPER 2)
3.1

Introduction
Substance use histories are endemic to the criminal justice system. Over 50% of

individuals in state prisons and jails meet the criteria for substance dependence or abuse
compared with only 5% of general populations (Bronson, Stroop, Zimmer, & Berzofsky, 2017;
James & Glaze, 2006). This becomes more pressing in the current era of opioid use and the
overdose epidemic. Individuals with justice involvement have long faced an increased risk of
overdose and death following release from prison or jail (Binswanger 2007) owing to relapse
after prolonged periods of substance abstinence. The most recent leading cause of death among
formerly justice-involved individuals in Washington State was overdose from opioids, compared
to overdose from cocaine in the early 2000s (Binswanger, Blatchford, Mueller, & Stern, 2013).
Further, over 50% of all overdose deaths among formerly justice-involved persons were found to
be due to polysubstance opioid use (Binswanger et al., 2013).
Polysubstance use (PSU) refers to the unique patterns of use that includes more than one
drug. PSU can be simultaneous (e.g., two or more substances at the same time), sequential (i.e.,
one substance followed by another), or regular interval (i.e., two or more substances used in the
same day/week/month). PSU involving opioids with a substance from another class is
increasingly common and is a substantial contributor to overdose deaths (Jones, Einstein, &
Compton, 2018; Ruhm, 2017).
Risk for overdose among justice-involved persons is highest in the first weeks after
release (Binswanger et al., 2013). Compounded with unique challenges to reentry such as barriers
to housing, employment, and health care, individuals returning to the community are significantly
burdened. It is crucial to understand the factors that are associated with post-release relapse
among justice-involved populations, amid consideration of high prevalence of PSU opioid use in

48

this population. As such, the current study examines pre-incarceration PSU opioid patterns and
other identified risk factors as predictors of post-release relapse.
3.1.1

Conceptual Framework
Conceptual consideration of risk factors for post-release relapse in the current study were

guided by the Behavioral Model for Vulnerable Populations (Gelberg, Andersen, & Leake, 2000).
The model posits that predisposing, enabling, and need factors typified by their relation to
traditional (i.e., general) and vulnerable populations, influence utilization of health services and
health status (see Figure 3.1). Predisposing factors exist before health needs, such as demographic
characteristics. Enabling factors affect the ability of an individual to secure necessary resources or
care, such as personal and economic resources. Need factors include health problems and
perceived health concerns. These factors are divided by traditional and vulnerable domains
according to their relation to general and vulnerable populations.
Previously, this model has been utilized to examine homeless populations (Kushel, Perry,
Bangsberg, Clark, & Moss, 2002; Stein, 2007), formerly incarcerated (Goshin & Byrne, 2012;
Oser, Bunting, Pullen, & Stevens-Watkins, 2016), and substance-using populations (Victor,
Kheibari, Staton, & Oser, 2018). Outcomes previously examined include emergency room use
(Kushel et al., 2002; Oser et al., 2016), substance use treatment (Victor et al., 2018), and postrelease relapse (Krishnan et al., 2013). The one known study to explore post-release relapse
examined relapse to cocaine and opioid use among a cohort of HIV-positive individuals sixmonths post-incarceration (Krishnan et al., 2013). Predisposing factors of homelessness and
marital status as well as need factors such as alcohol and drug use severity were significant
predictors of post-release cocaine and/or opioid use (Krishnan et al., 2013). However, this study
did not categorize factors by traditional or vulnerable domains.
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Increased risk of relapse is associated with traditional domain variables of younger age
(Kopak, Hoffmann, & Proctor, 2016) and unemployment (Evans, Hahn, Lum, Stein, & Page,
2009; Kadam, Sinha, Nimkar, Matcheswalla, & De Sousa, 2017; Steensma, Boivin, Blais, & Roy,
2005). Co-morbid physical and mental health problems can aggravate return to substance use
(Binswanger et al., 2012; Johnson et al., 2013; Hser et al., 2007; Mallik-Kane & Visher, 2008).
Qualitative explorations reveal that post-release relapse is often triggered by a myriad of
intersecting barriers including negative affect (Bunting et al., 2018; Johnson et al., 2013), mental
and physical health challenges (Binswanger et al., 2012; Johnson et al., 2013; Morash, 2010),
environmental triggers (Bunting et al., 2018; Leverentz, 2013; Morash, 2010), and economic
distress (Binswanger et al., 2012; Johnson et al., 2013) which can be considered in their relevance
to vulnerable populations. The risk of relapse, including an accelerated return to use, is high
among individuals with injection drug use (IDU) histories (Cepeda et al., 2015; DeBeck et al.,
2009; Genberg, Astemborski, Vlahov, Kirk, & Mehta, 2015). It is important to consider the
factors unique to vulnerable populations, especially those individuals reentering society, as they
have unique barriers to reintegration which can exacerbate their return to substance use. Justice
system involvement on its own may be associated with a shorter time to relapse (Hser et al.,
2007).
3.1.2

Relapse among justice-involved individuals
Rates of opioid use among justice-involved populations are estimated at 16-25%, such

that 1 in 4 females in prisons and jails and 1 in 6 males in prisons and jails report regular use of
opioids prior to their incarceration (Bronson et al., 2017). An estimated 24-36% of all individuals
with a heroin use disorder pass through the justice system in a given year (Boutwell, Nijhawan,
Zaller, & Rich, 2007). Additionally, intensity of opioid use is related to more recent justice
system involvement (Winkelman, Chang, & Binswanger, 2018). Relapse to opioids post-release
has been found to occur in as many as 75% of formerly incarcerated (Fox et al., 2015; Kinlock,
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Gordon, Schwartz, & O’Grady, 2008) as soon as 1-month post-release (Binswanger et al., 2013;
Lee et al., 2015).
Justice systems seek to reduce post-release relapse through a variety of prison treatment
modalities. A popular behavioral treatment is a therapeutic community (Chandler, Fletcher, &
Volkow, 2009). Guided by De Leon (2000), prison and jail therapeutic communities are typically
environmentally isolated communities which view substance use disorders from a whole-person
perspective with the primary goal to change the negative behavior, thinking, and feeling patterns
which precipitate substance use (De Leon, 2000; Inciardi, Martin, & Butzin, 2004). Therapeutic
communities have demonstrated efficacy at reducing relapse (Inciardi et al., 2004). However,
enrollment in aftercare is a critical component for positive outcomes, and diminished effects have
been observed over time (de Andrade, Ritchie, Rowlands, Mann, & Hides, 2018; Inciardi et al.,
2004).
3.1.3

Definitions of relapse
When considering occurrence of relapse, it is important to first discuss the theoretical and

operational definitions of relapse and the term’s use. Historically, substance use outcomes have
tended to be dichotomous such that an individual is either abstinent and successful or relapsed
and using (Miller, 1996). Dichotomous abstinent/relapse definitions imbue moral implications
and fail to consider the gradual process of recovery (Miller, 1996; White & Ali, 2010.; White,
2007). Considering substance use on a continuum is more representative of the lives of
individuals. For example, nicotine research has suggested trials measure prolonged abstinence
after an initial period where returning to nicotine use is not considered a relapse (Hughes et al.,
2003). Alcohol and nicotine research also consider relapse as measured by return to use for
consecutive days, rather than a sole event (Chung & Maisto, 2006; Hughes et al., 2003).
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Among opioid use, complete abstinence may often be advised as the ideal outcome given
the deleterious effects of these substances. It is often considered that individuals with previous
vulnerabilities may not be ideal candidates for a reduced use definition of recovery (White, 2007).
Definitions in the late 1980s referred to recovery as “reduction of drug use, criminal involvement
and unemployment” and “drug abuse and related behavior [that] are no longer problematic in the
individual's life” (Simpson & Marsh, 1986; Leukefeld & Tims, 1986)- both definitions that do not
require complete abstinence as measures of success. This distinction may be particularly
important for PSU. Recovery programs and ideologies vary in terms of PSU relapse such that
return to use of primary substance compared to return to use of any substance may trigger
different support responses. Often motivations for PSU include the preferred effects produced by
two or more substances (Ellinwood, Eibergen, & Kilbey, 1976; Leri, Bruneau, & Stewart, 2003).
What constitutes a relapse in instances of PSU, then, is particularly ambiguous.
Given an emphasis on person-first language and autonomy of individuals as active agents
in their own recovery (White & Ali, 2010), the current research allows individuals to determine if
their post-release substance use is a relapse event. While the term ‘relapse’ may be better
excluded and replaced, its use remains prevalent and particularly understood as part of peer
recovery groups. Thus, when an individual reports that they have relapsed, they may be reporting
that they have returned to problematic use as perceived in their own life.
3.1.4

Substances involved in relapse
The literature primarily focuses on relapse to preferred or primary substance, which

makes it difficult to fully understand the array of substances that individuals use during a relapse
event. When enrolled in treatment for a primary substance, individuals may turn to a new or
secondary substance. For example, a study of individuals enrolled in methadone treatment found
that approximately one-fourth began using benzodiazepines after entering treatment (Chen et al.,
2011). Increased use of alcohol and marijuana has been found among individuals in their first
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year of opiate abstinence (Bacchus, Strang, & Watson, 2000). Research indicates the role of the
endocannabinoid system in opioid dependence (Bisaga et al., 2015), and increased use of
marijuana during treatment for opioid use disorder has been observed (Heidebrecht, MacLeod, &
Dawkins, 2018). There may be circumstances where individuals self-medicate to ease withdrawal
symptoms, or individuals may replace their primary substance of use.
Examination of relapse within a polysubstance framework has not yet been explicitly
explored. Life-course understandings of substance use find that periods of abstinence and use
vary by substance (Hser et al., 2007). Given this heterogeneity, it is expected that experiences of
relapse will vary when PSU is explicitly considered.
3.1.5

Current Research
The current study seeks to understand the risk factors associated with post-release relapse

within consideration of PSU. While prior research has indicated high rates of post-release relapse
for individuals who use opioids (Binswanger et al., 2013; Fox et al., 2015; Kinlock et al., 2008;
Lee et al., 2015), it is unclear how PSU patterns in conjunction with relevant risk factors for
justice populations influence post-release substance use. The goal of this study was to identify
significant PSU opioid patterns which were used as independent predictors along with traditional
and vulnerable domain factors from the Behavioral Model for Vulnerable Populations in a
multivariate model of relapse in a justice-involved sample.

3.2
3.2.1

Methods
Sample
Data for the current study are from the Criminal Justice Kentucky Treatment Outcome

Study (CJKTOS). The study is ongoing since 2005 and the current cohort is a 2015-2017 cohort
consisting of both baseline and follow-up data as a result of a collaboration with the Department
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of Corrections (DOC) and University of Kentucky Center on Drug and Alcohol Research (UK
CDAR). Individuals entering DOC prisons, jails, and community custody are eligible for entry to
substance abuse program (SAP). The SAP is a six-month program following the therapeutic
community model (De Leon, 2000). Individuals are eligible for SAP if they have 12-24 months
remaining to serve on their sentences, a reported substance use history, and no recent disciplinary
violations. Individuals must provide consent to be included in the follow-up with contact
information. Consent to baseline assessment is included in DOC consent to treatment and written
consent at baseline is obtained for individuals who wish to be considered for the follow-up
survey.
Baseline assessments are provided at entry by DOC staff using computer assisted
personal interview (CAPI) software. UK CDAR uses telephone computer assisted personal
interviewing software (CAPI) for a proportionate follow-up survey 12-months post-release. There
were no significant differences between the greater SAP population and those included in the
follow-up. Of the individuals who consent to follow-up, a random sample proportionate to the
number of males and females released from prison, jails, and community custody programs are
selected for inclusion with a yearly target sample of 350. Follow-up rates were 80% (2015), 83%
(2016), and 84% (2017). Individuals were ineligible for follow-up if they moved out of state
(n=31) or were deceased (n=13). The DOC receives an aggregated yearly report of findings,
without individual data. A federal certificate of confidentiality was obtained and individuals were
informed that their information would not be shared with the DOC.
The resulting sample for years 2015-2017 included 1,044 individuals. The sample was
then limited to individuals from prison or jail SAP only (n=982), with a history of opioid use in
the 12-months prior to incarceration (n=816), and who reported using more than one substance on
a given day in the 30-days prior to incarceration (i.e., a PSU population) resulting in a final
sample of 501 individuals.
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3.2.2

Variables
3.2.2.1

Dependent Variables.

The primary outcome variable was a dichotomous measure of post-release relapse.
Individuals who reported the use of any substances (any drugs and/or alcohol) in the 12-months
post-release were asked if they considered their use to be a relapse (1=yes, 0=no to include no
relapse or no substance use). An additional dependent variable measuring days until relapse
through self-report of how many days an individual reported they were back in the community
before they first used alcohol/drugs (0-365) was included for use in a time-series model.
3.2.2.2

Polysubstance Use Patterns.

The independent variables of polysubstance use patterns were measured through
assignment to identified latent profiles. Previously (paper 1), these substances were used to form
latent profiles in a larger sample of the CJKTOS population. Through the use of latent profile
analysis, the larger study identified a six-profile model solution. The current research was
interested to know if the six PSU opioid profiles previously identified existed in the current
smaller population. Often referred to as validation, the replication of latent profiles is a common
sensitivity analysis to determine if profiles exist in different samples (Pastor, Barron, Miller &
Davis, 2007).
At baseline, individuals were asked if they had used a given substance in the 12-month
prior to their incarceration. For each substance an individual reported using, they were then asked
how many days in the 30-days prior to incarceration they used the substance (R: 0-30). The
following substances were examined: alcohol, cocaine, marijuana, heroin, non-prescribed
suboxone, non-prescribed opiates, amphetamines, and tranquilizers. Amphetamines included use
of methamphetamine, MDMA, and non-prescribed Ritalin. Tranquilizers included non-prescribed
use of benzodiazepines, ketamine, and muscle relaxers.
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To validate the six-profile solution previously found, the posterior probabilities of profile
membership from the baseline study were applied to the current sample of 501. The model
successfully converged, and fit statistics indicate that the six-profiles were a best fit for the data
(see Table 3.1). Further, the latent indicators of mean number of prior 30-day use were compared
and the follow-up profiles remained the same in terms of substantive meanings and structure.
Once the latent profiles were validated, individuals were assigned to profiles based on
their likelihood of membership (i.e., the three-step method). This membership is independent in
that individuals can only belong to one profile. Characteristics of the PSU profiles are in Table
3.2. The six profiles were given descriptive profile titles. The Primarily Alcohol P1 profile
consisted of individuals with near daily use of alcohol and co-use of marijuana and opiates. The
Primarily Heroin P2 profile was characterized by near daily use of heroin along with co-use of
marijuana and opiates. Individuals in the Low PSU P3 profile had lower use compared to other
profiles but co-use of marijuana and opiates. The High PSU P4 profile was differentiated by
diverse PSU to include near daily use of tranquilizers and high co-use of amphetamines. The
Primarily Suboxone P5 profile contained individuals with near daily use of illicit suboxone and
co-use of marijuana and opiates. The Stimulant-Opioid P6 profile was characterized by diverse
PSU patterns to include near daily use of cocaine and co-use of marijuana, heroin, opiates, and
tranquilizers.
3.2.2.3

Traditional Domain Variables.

All traditional domain variables were from baseline assessments. Utilizing the Behavioral
Model for Vulnerable Populations (Gelberg et al., 2000) as a guiding framework, variables were
categorized in the domains of predisposing, enabling, or need. Predisposing traditional domain
variables included age (measured continuously), education (measured continuously with GED=12
years), race (1=white, 0=nonwhite), marital status (1=married, 0=single/divorced/widowed), and

56

gender (1=male 0=female). Pre-incarceration employment was considered dichotomously
(1=unemployed).
The enabling traditional domain included a measurement of economic hardship. This
was a summative scale adapted from the Survey of Income and Program Participation (R:0-8,
α=0.87) which includes eight dichotomous measures of difficulty meeting needs of food, housing,
clothing, and medical care (Beverly, 2001). Higher scores indicate more economic hardship.
The need traditional domain consisted of a dichotomous variable measuring individual’s
chronic pain as described to them as, “…pain persists or recurs for 3 months or longer. It
typically includes pains like what you get from arthritis, fibromyalgia or unhealed injuries. It does
not include minor headaches, or temporary pain from minor injuries.” (1=yes). Pre-incarceration
physical and mental health were considered via the questions, ““Thinking about your
[physical/mental] health, which includes [physical illness and injury/stress, /depression and
problems with emotions,] during the 30 days prior to this incarceration, how many days was your
[physical/mental] health not good?” (R:0-30).
3.2.2.4

Vulnerable Domain Variables.

Variables in the vulnerable domain were from baseline assessments. The predisposing
vulnerable domain included pre-incarceration homelessness (1=yes) and the number of years the
individual was incarcerated. The county an individual lived in prior to incarceration was coded
using a rural-urban coding scheme (Ingram & Franco, 2014) collapsed to a dichotomous
measurement such that 1=rural and 0=urban.
The enabling vulnerable domain included a dichotomous measure indicating if the
individual reported being told they had a learning disability. Recovery support was measured via
a dichotomous question that asked, “In the 30 days prior to this incarceration, did you have
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contact with family or friends who were supportive of your recovery?” The variable was coded
such that a value of 1 indicated the individual had no recovery support.
Need vulnerable domain variables included lifetime injection drug use history (1=yes)
and being told by a health professional they had the hepatitis c virus (HCV; 1=yes). Anxiety and
depression symptoms in the 12-months prior to incarceration were measured using an adapted
dichotomous version of the Patient Health Questionnaire-9 (PHQ-9; Spitzer, Kroenke, Williams,
& Group, 1999) (R: 0-9), and the Generalized Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke,
Williams, & Löwe, 2006) (R:0-7). Scores above 2 would indicate a mild disorder, with increasing
severity as scores increase. In the current study the internal reliability was strong for both scales,
with PHQ-9 α=0.93 and GAD-7 α=0.97
3.2.3

Analytic Plan
Bivariate analyses of traditional and vulnerable domain variables using Fisher exact and

ANOVA tests determined if PSU profiles were significantly different from each other in Table
3.3. Additionally, bivariate examination of the concept of relapse in the dependent variable are
reported in Table 3.4. Fisher exact results examine the differences between individuals who
report perceiving their substance use as a relapse (the dependent variable) and those who reported
using a substance, but did not perceive their use to be a relapse.
Block-wise logistic regression examined the association between post-release relapse and
(1) latent profiles, (2) traditional domain variables, (3) vulnerable domain variables with variables
in block 2 and 3 only remaining in next block when significant at a conservative p<.10 or above
for a (4) complete model. A secondary analysis examined the days until relapse using a Coxproportional hazard model. In the Cox-proportional hazard model, individuals were right
censored such that those not reporting relapse were given a value of 365 days. Five individuals
report relapsing at 0 days, indicating they relapsed immediately after release. These individuals,
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in order to be included in the Cox model which requires positive integers, were coded as having a
relapse event at day 1. Supplementary analyses include bivariate Fisher’s exact and t-tests for
significant differences on the specific substance used post-release by latent profile. Tests for
collinearity revealed no issues and variance inflation factors were less than 2.0. All analyses were
performed with Stata (SE) 15.1.

3.3
3.3.1

Results
Characteristics of Sample
Sample characteristics are detailed in Table 3.3. The population was predominantly

white, non-married males, who were on average age 33 with 13 years of education. The majority
of participants reported unemployment prior to incarceration (64.87%). Individuals reported an
average of two instances of economic hardship, on a scale ranging from zero to eight.
Approximately one-third of the sample reported chronic pain, with an average week of poor
physical health and 11 days of poor mental health in the 30-days prior to incarceration.
Nearly one in five participants were homeless prior to incarceration. Individuals were
incarcerated an average of two years. The sample was nearly evenly split between rural and urban
residents. One-fourth of the sample reported a learning disability. Nearly 30% stated they had no
friends or family who were supportive of their recovery in the 30-days prior to incarceration. A
majority (61.9%) reported IDU, and 14% reported HCV positive serostatus. On average,
individuals met the criteria for mild to moderate depression and anxiety as indicated by average
scores above the value of two. The total sample relapse rate was 40% with an average of 244 days
until relapse (right-censored).
There were no significant differences between profiles on any of the traditional domain
variables (p>.05). Among vulnerable domain variables, profiles were significantly different due
to pre-incarceration homelessness (p<.05). Specifically, nearly 30% of Primarily Heroin P2 and
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Stimulant-Opioid P6 individuals reported homelessness. Individuals also differed due to
incarceration history such that Primarily Heroin P2 individuals were incarcerated for a shorter
period than High PSU P4 (Tukey test p<.05). Profiles also differed significantly due to rural
versus urban residence (p<.001). Primarily Heroin P2 lived in largely urban counties, compared
with Primarily Suboxone P5 who largely lived in rural counties.
Significant differences were observed among IDU and HCV, such that Primarily Alcohol
P1 had the lowest rates of both, while the Primarily Heroin P2 had greatest reports of both IDU
and HCV. Profiles differed significantly in both depression and anxiety symptoms, and TukeyKramer tests performed after ANOVA indicated that these differences were significant between
Low PSU P3 and High PSU P4. Additionally, significant differences of depression
symptomology were found between High PSU P4 and Primarily Suboxone P5 (p<.01). The
dependent variables of post-release relapse and days until relapse were also significantly different
between profiles. The Low PSU P3 group was least likely to report a relapse, whereas Primarily
Alcohol P1 and Primarily Suboxone P5 profiles were most likely to report post-release relapse.
Post-hoc Tukey tests indicated that the Primarily Alcohol P1 group had significantly less days to
relapse compared to the Low PSU P3 group.
Table 3.4 contains t-test and Fisher’s exact test results for variables among those who
considered their post-release substance use a relapse (n=203) and those who reported substance
use post-release but did not consider it a relapse (n=87). Among latent profiles, a significance
difference of p<.01 was found. Of note, all of the individuals in the Primarily Alcohol P1 group
stated their post-release use was a relapse event.
Observing variables in the traditional domain, perceptions of whether post-release
substance use was a relapse differed significantly by age, such that those who reported that it was
a relapse were likely to be younger (p<.05). Additionally, individuals who perceived post-release
use as relapse were more likely to have pre-incarceration recovery support (p<.01). In the
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vulnerable domain, individuals with positive HCV serostatus were more likely to perceive their
substance use as a relapse (p<.01). Further, among the dependent time variable, individuals who
reported that post-release substance use was not a relapse had greater number of days until use
(p<.01).
3.3.2

Multivariate Models Predicting Post-Release Relapse
Adjusted odds ratios for the stepwise logistic regression models examining association

with post-release relapse are presented in Table 3.5. In Model 1, with latent profiles alone, the
Primarily Alcohol P1 and Primarily Suboxone P5 groups were most likely to report relapse. This
finding remained into the final model (Model 4). Three traditional domain variables were
significant at the p<.10 level or above and remained into the full model: age (p<.001), gender
(p<.05), and chronic pain (p<.10). Of vulnerable domain variables entered in Model 3, only HCV
status (p<.01) was significant and remained into the full model.
Examining the full Model 4, individuals were more likely to report post-release relapse if
they were characterized by Primarily Alcohol P1 PSU patterns (AOR: 2.80; p<.01) and Primarily
Suboxone P5 (AOR: 2.39; p<.01) PSU patterns. With increasing age, individuals were less likely
to report post-release relapse (AOR: 0.94; p<.001). Males had a 67% increased likelihood of
relapse compared to females (AOR: 1.67; p<.05). Individuals who were HCV positive were also
at increased risk of post-release relapse (AOR: 2.47; p<.001).
3.3.3

Days until Relapse
To further consider the relationship with PSU patterns and post-release relapse, Cox-

proportional hazard models examined days until relapse (n=501, results not shown). The
dependent variable remained the same but an additional factor of time to relapse was considered.
Individuals were right-censored such that those who did not experience a relapse were given the
value of 365 (max number of days in follow-up period). Results did not differ from the
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multivariate models in Table 3.5, such that the Primarily Alcohol P1 (HR: 1.59, p<.05) and
Primarily Suboxone P5 (HR: 1.38, p<.05) groups were at accelerated risk for relapse. Considered
in conjunction with the results from Table 3.5, results indicate that not only are these profiles at
risk for relapse, but they are at risk of relapsing sooner than other profiles (see Figure 3.2). The
only significant covariate in the Cox-models was the traditional domain variable of age, such that
being older reduced time to relapse (HR: 0.98; p<.01).
3.3.4

Supplementary Analyses
At follow-up, individuals were asked which substances they used in the previous 12

months since release. Table 3.6 contains the percentages and Fisher exact values for PSU profiles
and post-release substance use. Significant differences at the p<.05 level or above are observed
for post-release use of heroin (p<.001) and tranquilizers (p<.05). Specifically, the Primarily
Heroin P2 group was most likely to report using heroin post-release and the Stimulant-Opioid P6
group reported highest use of tranquilizers. These substances align with prominent substance
patterns observed in their pre-incarceration latent profiles.
Given that the Primarily Alcohol P1 and Primarily Suboxone P5 groups were most likely
to report post-release relapse, examination of their post-release use is warranted. Approximately
one-third of individuals characterized by Primarily Alcohol P1 reported post-release use of
alcohol, marijuana, opiates, and amphetamines. Of the Primarily Suboxone P5 group, post-release
use was largely characterized by alcohol, marijuana, suboxone, opiates, and amphetamine use.

3.4

Discussion
The current study explored the association of pre-incarceration PSU opioid patterns with

post-release substance use. Guided by the Behavioral Model for Vulnerable Populations (Gelberg
et al., 2000), findings indicate unique substance use, traditional, and vulnerable domain risk
factors for return to substance use post-release. The relapse rate in the current justice-involved
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population was 40% and ranged 34-58% by PSU profiles indicating heterogeneity by substance
patterns. This rate is lower than post-release relapse rates found in other research (Fox et al.,
2015; Kinlock et al., 2008) possibly owing to the treatment program individuals were enrolled in
during their incarcerations.
Two PSU profiles were found to be at increased and accelerated risk for relapse. Thus,
while some research has indicated risk factors are similar for relapse and proposed the relapse
process to be similar across substances (Witkiewitz & Marlatt, 2004, 2007), the findings here
support research which indicates recovery paths are likely to differ by substances (Castro,
Barrington, Walton, & Rawson, 2000; Hser et al., 2007).
Primarily Alcohol P1 individuals had lower than average risk factors such as preincarceration homelessness, IDU histories, and HCV. However, individuals in this group were
more likely to report relapse even when controlling for other risk factors. Of the individuals
characterized as Primarily Alcohol P1, all reported their post-release use as a relapse compared to
reporting use but no relapse.
Some research indicates individuals return to alcohol use may be influenced more by
proximal risks- or immediate triggers-compared to distal risks (Witkiewitz & Masyn, 2008). In
many individuals, posttreatment alcohol use tends towards dichotomy of abstinence or excessive
use and the return to heavy drinking patterns occurs quickly among those who relapse (Hufford,
Witkiewitz, Shields, Kodya, & Caruso, 2003). Returning to the community encompasses a
myriad of difficulties which may serve as a proximal trigger. Alcohol use is the most commonly
reported substance used by men returning to communities from prison (Mallik-Kane & Visher,
2008), perhaps owing to its legal status and the ease by which it can be obtained. The Primarily
Alcohol P1 high pre-incarceration use of alcohol and high post-release reported use make this
group highly vulnerable to post-release relapse.
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The high rate of reported relapse, as opposed to return to use with no relapse, may be
explained by the high presence of peer-recovery groups in prisons and jails and mandated as part
of parole (Leverentz, 2013). The celebration of sobriety birthdays in programs such as Alcoholics
Anonymous indicate a preference for abstinence, and individuals who have been involved in
these programs may be more likely to self-cite relapse.
While the primary substance for Primarily Alcohol P1 was alcohol, it is important to
highlight that this profile had moderate PSU of marijuana and opiates both pre and postincarceration. Therefore, measuring their return to a primary substance (i.e., alcohol) may not
have accurately captured their post-release relapse behavior. Rather, risk factors unique to alcohol
use could have accelerated their return to use when combined with other high-risk substances.
Marijuana is the second most frequently reported substance used post-release (Mallik-Kane &
Visher, 2008) and relapse to opiates is high as well (Fox et al., 2015) making this profile of PSU
individuals highly vulnerable.
The Primarily Suboxone P5 profile were also more likely to have a post-release relapse
event, and at accelerated rate. This profile was unique in individuals’ near daily use of illicit
Suboxone as well as co-use of marijuana and opiates. These substances were also reported postrelease. Individuals in this profile were unique in that they were more likely to live in rural areas
compared to the other profiles. It is likely that this influenced their preferred substance patterns
(Young, Havens, & Leukefeld, 2010).
Motivations for illicit buprenorphine use includes support for both euphoric effects as
well as self-treatment of opioid dependence (Bazazi, Yokell, Fu, Rich, & Zaller, 2011;
Hakansson, Medvedeo, Andersson, & Berglund, 2007; Yokell, Zaller, Green, & Rich, 2011).
However, it is unclear why return to illicit Suboxone would occur post-treatment. As of 2015 the
KY DOC began offering injectable naltrexone to individuals enrolled in SAP. Individuals with
pre-incarceration preference for Suboxone may continue to prefer Suboxone as a treatment
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modality post-release, or their use may have been unrelated to curbing opioid withdrawal. Given
Suboxone’s primary use as a treatment modality for opioid use disorder, less is known about the
recovery trajectories of individuals who primarily report illicit Suboxone use.
Considering the Behavioral Model for Vulnerable Populations (Gelberg et al., 2000),
traditional domain variables of age and gender were significantly associated with post-release
relapse. Substantial literature exists to support these relationships (Evans et al., 2009; Kopak et
al., 2016; Walitzer & Dearing, 2006). In the vulnerable domain, HCV status was a robust
predictor of post-release relapse. Complex physical health problems can exacerbate reentry
difficulties (Binswanger et al., 2012). HCV is typically prevalent among individuals with more
extensive substance use histories (Klinkenberg et al., 2003; Rosenberg, Drake, Brunette, Wolford,
& Marsh, 2005; Shapatava, Nelson, Tsertsvadze, & Rio, 2006), and this previous history may
indicate individuals are more likely to return to use. Further, there are risky behaviors correlated
with HCV serostatus (Koblin, Factor, Wu, & Vlahov, 2003; Vescio et al., 2008; Willner-Reid,
Belendiuk, Epstein, Schmittner, & Preston, 2008), and its significance may reflect underlying
latent variables.
The current research made contributions to previous literature on relapse through the
focus on a high-risk criminal justice sample and the use of longitudinal data. This study is also
unique given the focus on PSU opioid patterns and highlighting the importance of PSU in the
relapse literature. There are, however, limitations to consider. The data included are based on
self-reports from a justice-involved sample. While this allowed for a unique definition of relapse
with more autonomy, it is plausible that the amount of substance use is underreported. While the
University oversees the follow-up data collection, it is possible individuals still feared negative
consequences from the DOC for reporting illegal behavior at follow-up.
In the current study, PSU is operationalized as regular interval use among a PSU sample.
That is, while individuals had self-reported histories of using more than one substance on a given
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day, the latent profiles captured regular interval PSU and were not able to measure simultaneous
or sequential PSU patterns. Future research should consider these patterns when examining
follow-up outcomes. The current study provided insights into the patterns of use associated with
relapse but leaves motivations and contextual understandings of relapse unexplored. Future
qualitative research that explores the motivations for pre-incarceration PSU as well as more
specific details about post-release relapse would be beneficial so as to design effective
interventions.
3.4.1

Conclusions
The findings of the current study indicate that among users of opioids who return to the

community after prison, there is a continuum of risk. Elevated risk of relapse among individuals
who co-use marijuana and opiates with alcohol or illicit Suboxone were found. Understanding
individuals’ pre-incarceration patterns of PSU may assist in mitigating risk to relapse post-release
if appropriate interventions are made available. Findings indicate significant heterogeneity among
PSU justice-involved populations and the period of incarceration provides opportunity to
implement targeted interventions and provide aftercare planning. Further, both traditional and
vulnerable domains of the Behavioral Model for Vulnerable Populations provided significant
predictors indicating the utility of considering this model for post-release relapse in future
research. The reduction of post-release substance use improves outcomes for the lives of
individuals, along with cost-savings for communities and justice systems.
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Table 3.1 Fit statistics for latent profile validation analysis
6,569 Baseline
Sample
AIC
BIC

501 Follow-Up Cohort

Number of
AIC
BIC
Profiles
1
409677.5
409786.1
30960.7
31028.2
2
402295.7
402465.5
30073.9
30179.3
3
400521.7
400752.6
29921.7
30065.0
4
400005.1
400297.1
30231.8
30413.1
5
394654.1
395007.2
30127.9
30347.1
6
393898.7
394312.9
29810.8
30068.0
Notes: AIC= Akaike’s information criterion; BIC= Bayesian Information
criterion; bolded indicates selected latent profile
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Table 3.2 Latent profile conditional means for polysubstance opioid use (n=501)
Profile 1

Profile 2

Primarily
Alcohol
P1

Primarily
Heroin
P2

27.66
3.08
13.95
1.77
1.45
11.14
6.82

3.81
1.25
11.24
28.85
2.71
15.14
5.77

2.80
0.62
11.98
0.89
1.41
16.51
8.09

10.27
1.97
13.68
7.45
9.36
19.79
9.84

6.15
1.22
13.67
1.94
28.49
13.30
8.37

8.68
28.13
14.90
13.55
7.97
17.21
6.09

2.85

4.29

2.77

28.71

4.23

11.11

Profile
6.19%
15.97%
42.91%
Prevalence
Note: shading highlights most prevalent substances

15.17%

8.58%

11.18%

Descriptive
profile
abbreviation
Latent Profile
indicators: Prior
30- day use
Alcohol
Cocaine
Marijuana
Heroin
Suboxone
Opiates
Amphetamin
es
Tranquilizers

Profile 3

Profile
4
Low PSU High
P3
PSU
P4
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Profile 5

Profile 6

Primarily
Suboxone
P5

Stimulant
-Opioid
P6

Table 3.3 Characteristics of study population (n=501)

Primarily
Heroin P2

Low PSU
P3

30.54
(6.71)
11.77
(2.10)
90.00
38.75

32.99
(7.70)
11.83
(2.17)
86.05
34.42

33.33
(8.82)
12.21
(2.53)
86.84
35.53

31.81
(6.97)
11.65
(1.97)
83.72
20.93

32.55
(6.91)
11.78
(1.81)
75.00
46.43

.14

72.65
21.36
2.10
(2.52)
30.34

80.65
12.90
2.42
(2.78)
32.26

68.75
22.50
2.24
(2.75)
26.25

72.09
20.93
1.91
(2.40)
29.30

67.11
19.74
2.25
(2.57)
44.74

79.07
30.23
1.70
(2.11)
23.26

78.57
21.43
2.61
(2.67)
25.00

.62
.45
.34

7.40
(11.97)

9.42
(13.45)

6.47
(11.35)

9.25
(12.88)

13.52
(14.15)

10.12
(13.32)

15.31
(14.21)

8.32
(12.03
)
9.51
(13.83
)

6.96
(12.01
)
10.91
(13.54
)

.50

11.54
(13.80)

7.15
(12.12
)
12.52
(14.30
)

20.16
2.23
(1.74)

16.13
2.60
(2.36)

28.75
1.71
(1.25)

14.42
2.21
(1.72)

23.68
2.61
(1.54)

16.28
2.17
(1.46)

30.36
2.41
(2.23)

.02
.02

52.69

58.06

23.75

59.53

56.58

79.07

39.29

Learning
disability
No
recovery
support
IDU

25.75

29.03

28.75

21.40

26.32

34.88

28.57

.00
1
.44

29.74

29.03

30.00

30.23

31.58

25.58

28.57

.99

61.88

48.39

81.25

50.70

71.05

65.12

69.64

HCV
Depressio
n

14.17
4.44
(3.52)

9.68
4.26
(3.55)

23.75
5.07
(3.43)

9.77
4.01
(3.53)

18.42
5.61
(3.31)

18.60
3.35
(3.48)

10.71
4.55
(3.46)

.00
1
.03
.00
2

Anxiety

3.71
(3.23)

3.84
(3.36)

3.51
(3.18)

3.30
(3.22)

4.68
(3.12)

3.74
(3.32)

4.14
(3.15)

Dependent
Variables
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p-value

Primarily
Alcohol
P1
33.84
(8.61)
12.06
(1.65)
77.42
70.97

Education
level
White
Unemploy
ed
Male
Married
Economic
hardship
Chronic
pain
Physical
health
days
Mental
health
days
Vulnerable
Domain
Homeless
Years
incarcerate
d
Rural

Stimulant
-Opioid
P6
Primarily
Suboxone
P5
High PSU
P4

Total
Sample
32.55
(7.67)
11.87
(2.13)
84.83
64.87

Traditional
Domain
Age

.70
.17
.16

.07

.07

.03

Table 3.3 (continued)

p-value

StimulantOpioid P6

Primarily
Suboxone
P5

High PSU
P4

Low PSU
P3

Primarily
Heroin P2

Primarily
Alcohol
P1

Total
Sample

Post
relapse
Days
until
relapse

40.52

58.06

41.25

34.42

40.79

58.14

39.29

.03

244.35
(153.15)

173.64
(169.01)

245.79
(152.60)

261.37
(148.07)

249.43
(148.87)

191.28
(156.07)

249.95
(154.42)

.01

(Rightcensored)

Note: p-values obtained through ANOVA and Fisher exact tests
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Table 3.4 Examination of dependent variable: post-release relapse vs. post-release
substance use
Post-release
relapse reported
(N=203)

Substance use,
but no relapse
(N=87)

Latent Profiles
Primarily Alcohol P1
100.0
0
Primarily Heroin P2
70.21
29.79
Low PSU P3
64.35
35.65
High PSU P4
67.39
32.61
Primarily Suboxone P5
86.21
13.79
Stimulant-Opioid P6
62.86
37.14
Traditional Domain
Age
30.93 (7.54)
33.14 (8.28)
Education level
12.72 (1.86)
13.07 (2.41)
White
87.19
82.76
Unemployed
65.52
60.92
Male
76.85
78.16
Married
21.67
19.54
Economic hardship
2.01 (2.52)
2.21 (2.45)
No recovery support
25.62
42.53
Chronic pain
31.03
31.03
Physical health days
7.39 (11.94)
8.22 (12.87)
Mental health days
11.62 (13.79)
10.69 (13.88)
Vulnerable Domain
Homeless
18.23
22.99
Years incarcerated
1.59 (1.60)
1.25 (1.24)
Rural
53.69
44.83
Learning disability
27.09
27.59
IDU
66.50
60.92
HCV
18.72
6.90
Depression
4.39 (3.48)
3.92 (3.52)
Anxiety
3.84 (3.24)
3.38 (3.23)
Dependent Variables
Post relapse
--Days until relapse
67.24 (71.13)
99.78 (102.33)
(Right-censored)
Note: p-values obtained through t-tests and Fisher’s exact tests
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p-value

.01

.03
.18
.36
.50
.88
.75
.54
.01
1.0
.60
.60
.42
.07
.20
1.0
.42
.01
.42
.26

.002

Table 3.5 Stepwise logistic regression predicting post-release relapse; Adjusted odds
ratios (standard errors) reported (n=501)
Latent Profiles
Primarily Alcohol P1
Primarily Heroin P2
High PSU P4
Primarily Suboxone P5
Stimulants-Opioid P6
Traditional domains
Age
Education level
White
Unemployed
Male
Married
Economic hardship
No recovery support
Chronic pain
Physical health days
Mental health days
Vulnerable domains
Homeless
Years incarcerated
Rural
Learning disability
IDU
HCV
Depression
Anxiety

Model 1

Model 2

Model 3

Model 4

2.64**
1.34
1.31
2.65***
1.23

2.94**
1.18
1.32
2.57**
1.23

2.78**
1.16
1.15
2.29*
1.22

2.80**
1.06
1.20
2.39**
1.19

0.94***
0.94
1.48
0.90
1.55
1.08
0.98
0.74
1.46
1.00
1.00

0.93***
---1.60*
---1.46

0.94***

1.67*

1.44

0.72
1.08
1.12
0.95
1.17
2.33**
2.47***
0.98
1.04
12.71* 40.85*** 49.74***
44.30***
0.0188
0.0604
0.0735
0.0655
Note: Latent profile 3, low PSU is reference group; stepwise technique includes variables
significant in previous model at p<.10 remain into next model; significance indicated by *p<.05,
**p<.01, ***p<.001
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Cocaine

Marijuana

Heroin

Suboxone

Opiates

Ampheta
mines

Tranquili
zers

Primarily
Alcohol
P1
Primarily
Heroin P2
Low PSU
P3
High PSU
P4
Primarily
Suboxone
P5
StimulantOpioid P6
p-value

Alcohol

Table 3.6 Post-release substances used (%) among those reporting relapse by latent
profile (n=203)

29.03

3.23

22.58

12.90

16.13

29.03

32.26

0.00

31.25

11.25

28.75

41.25

16.25

43.75

17.50

13.75

25.12

4.65

27.44

9.30

13.49

26.98

20.93

6.98

28.00

8.00

24.00

9.33

16.00

29.33

10.67

13.33

34.88

2.33

39.53

6.98

27.91

41.86

25.58

4.65

32.14

12.50

23.21

23.21

16.07

32.14

25.00

16.07

.71

.11

.47

.001

.37

.08

.09

.03

Note: p-values obtained through Fisher’s exact tests
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Figure 3-1 Behavioral Model for Vulnerable Populations (Gelberg, Andersen, & Leake,
2000) as applied in current research
Predisposing

Enabling

Need

Traditional Domain
Age
Marital status
Education
Employment status
Gender
Race

Traditional Domain
Economic hardship

Traditional Domain
Chronic Pain
# of poor physical
health days
# of poor mental
health days

Vulnerable Domain
Homelessness
Incarceration history
Rurality

Vulnerable Domain
Learning Disability
Recovery support

Vulnerable Domain
IDU
HCV
Depression
Anxiety

Measured pre-incarceration
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Health Behavior

Post-release
relapse

Figure 3-2 Days until relapse by latent profile
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CHAPTER 4.
POST-RELEASE HEALTH SERVICE UTILIZATION: AN APPLICATION OF
THE BEHAVIORAL MODEL OF VULNERABLE POPULATIONS TO A POLYSUBSTANCE
POPULATION (PAPER 3)
4.1

Introduction
Substance use and justice-involvement are inextricably linked, such that the majority of

justice-involved individuals meet the criteria for substance use disorder (Bronson, 2017).
Specifically, the prevalence of opioid use disorder in prisons and jails is pronounced. More than
half of individuals with prescription opioid use disorder and over 75% of individuals reporting
past year heroin use have prior justice-involvement (Winkelman, Chang, & Binswanger, 2018).
Post-release rates of relapse and risk of overdose are high (Binswanger, Blatchford, Mueller, &
Stern, 2013; Binswanger et al., 2007). Further complicating the intersection of justiceinvolvement with substance use is polysubstance use (PSU) or the consumption of more than
substance during the same timeframe.
PSU is common among justice populations, as 30-74% of currently incarcerated
populations report using more than one substance prior to their incarceration (Kubiak, 2004; Lo
& Stephens, 2000). Patterns of PSU continue to be observed post-release such that 56% of
overdoses among a sample of recently released individuals involved PSU. While justice-involved
populations have higher rates of mental and physical health problems compared to general
populations (James & Glaze, 2006; Mallik-Kane & Visher, 2008), PSU populations have marked
histories as well (Betts et al., 2015; Carlson et al., 2014; Darke & Hall, 1995; Feaster et al., 2016;
Quek et al., 2013) indicating that these comorbidities may be more pronounced among justiceinvolved populations with PSU histories.
Previous research indicates that formerly justice-involved populations are prodigious
consumers of health care, most notably cost-intensive services such as emergency room (ER) care
(Leukefeld, et al., 2006; McCorkel, et al., 1998; Schnittker, Uggenm Shannon, & McElrath,
2015). Frequent utilizers of ER care make up 4-8% of the ER population, yet 21-28% of ER visits
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(Schnittker et al., 2015). While individuals who use substances have pronounced health needs,
the use of ER services in lieu of a regular source of care is costly and creates health service gaps
furthering poor health outcomes among this population (Laine et al., 2001). A study of
individuals with substance use histories in Tennessee found an estimated $777 million in extra
ER charges due to increased ER use among the studied population (Rockett, Putnam, Jia, Chang,
& Smith, 2005). Further, individuals with poorer health status are more likely to engage in postrelease care (Leukefeld, et al., 2006). Given the higher comorbidity of mental and physical health
problems among PSU populations, the examination of post-release service utilization among this
population is warranted.
Justice-involved PSU populations represent a vulnerable population, when considering
their pronounced risk for poor outcomes. The post-release consumption of health care among this
population is important to examine, within a framework that considers their unique
vulnerabilities. The overall purpose of this study is to utilize the Behavioral Model for Vulnerable
Populations to examine the utilization of two health services (ER care, outpatient) 12-months
post-release given pre-incarceration PSU patterns.
4.1.1

Behavioral Model for Vulnerable Populations
The Behavioral Model for Vulnerable Populations (Gelberg, Andersen, & Leake, 2000) is

a revised version of the 1960’s Behavioral Model (Andersen, 1968) adapted to consider the
factors relevant to vulnerable populations (Aday, 1994). Factors are considered based on their
relevance to the current vulnerable population being considered. The framework consists of three
categories of factors: predisposing, enabling, and need, that are divided into two domains,
traditional and vulnerable, as relevant to general and vulnerable populations as predictors of
health service utilization (see Figure 4.1).
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Predisposing factors refer to those that exist before health needs, such as
sociodemographic variables and values. In the traditional domain, this would include age,
education, race, employment status, gender, or marital status. Previous research has found older
individuals (Gelberg et al., 2000, 2012; Varga & Surratt, 2014), those with higher education
(Pullen, Perry, & Oser, 2014; Varga & Surratt, 2014), and married individuals are more likely to
access care, indicating the utility of considering predisposing traditional domain variables.
Predisposing factors in the vulnerable domain are specific to justice-involved or
substance using populations in the current research. Homelessness (Kushel, Perry, Bangsberg,
Clark, & Moss, 2002) and incarceration history (Gelberg et al., 2012; Kulkarni et al., 2010;
Nowotny, 2017; Webster et al., 2006) are associated with decreased access to routine health
services, yet associated with increased ER utilization (Kim, Kertesz, Horton, Tibbetts, & Samet,
2006; Kushel et al., 2002; Stein, Andersen, Robertson, & Gelberg, 2012). Further, rurality is
associated with diminished access to health services (Webster et al., 2006), and serves as a
predisposing vulnerable variable in the current study.
Enabling factors reference elements that affect the ability of the population to secure
resources or care. Enabling traditional factors include income and economic distress, such that
individuals with greater economic need are less likely to have access to care (Gelberg et al., 2000;
Kushel et al., 2001; Teruya et al., 2010). In the vulnerable domain, enabling factors can include
measures of social support. The relationship between support and health service utilization is not
as clear, with research finding mixed results of both increased (Nowotny, 2017; Pullen et al.,
2014; Weinreb et al., 2006) and decreased access to care (Pullen et al., 2014). Further, the current
research considers learning disability as an enabling vulnerable variable, given the pronounced
prevalence of learning disabilities among justice-involved populations (Freudenberg, 2001) which
may affect their ability to navigate complex health care systems. Previous research indicates
decreased utilization of health services among individuals with developmental or intellectual
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disabilities (Havercamp, Scandlin, & Roth, 2004; Sowney & Barr, 2004), yet the effect of
learning disability among justice population’s use of health services remains unexplored.
Need factors refer to the perceived and actual health problems of traditional and
vulnerable populations. In the traditional domain this has previously included measurements of
self-rated health or chronic health conditions (Varga & Surratt, 2014). More relevant to the
current population, need vulnerable factors would include mental health problems and infectious
diseases such as hepatitis C virus (HCV) (Gelberg et al., 2012). Given the correlation between
injection drug use (IDU) and infectious diseases (Van Handel et al., 2016), consideration of IDU
within the need vulnerable domain is also warranted. Previous research indicates need factors in
both the vulnerable and traditional domains to be important correlates of health care access
(Brubaker et al., 2013; Gelberg et al., 2012; Oser et al., 2016; Nowotny, 2017; Rhoades et al.,
2014; Teruya et al., 2010; Varga & Surratt, 2014; Webster et al., 2006).
The predictive validity of the traditional and vulnerable domains has been found to vary
according to the health service examined (Katerndahl & Parchman, 2002; Oser et al., 2016; Varga
& Surratt, 2014; Victor et al., 2018). For example, many of the factors associated with a
decreased access to outpatient care (e.g., incarceration history, comorbid health problems) are
significant predictors of increased emergency room utilization (Frank, Linder, Becker, Fiellin, &
Wang, 2014; Kushel et al., 2002). While the utility of the domains is clear from prior research, it
remains to be seen how PSU affects health care utilization.
The post-release period includes a heightened risk of death for justice-involved
populations (Binswanger et al., 2007; Spaulding et al., 2011). Not only are individuals at
increased risk for overdose (Binswanger et al., 2007, 2013), but death due to health problems of
human immunodeficiency virus (HIV), cancer, and liver cirrhosis account for excess mortality
among previously incarcerated populations (Spaulding et al., 2011). The post-release period is
fraught with struggles which often supersede the continuity of health care, such as securing

79

housing, or are in themselves barriers to receiving health care, such as unemployment (Dumont,
Brockmann, Dickman, Alexander, & Rich, 2012). It is a pressing concern to understand the
factors associated with the utilization of post-release health services.
4.1.2

Current research
The current study contributes to previous literature by examining the health service

utilization 12-months post-release among a cohort of polysubstance-opioid using individuals.
While the Behavioral Model for Vulnerable Populations (Gelberg et al., 2000) has examined
post-incarceration health service utilization, its use remains limited among this population and
has been most often examined among specialty subgroups including women (e.g., Oser et al.,
2016; Victor et al., 2018) and HIV-subpopulations (e.g., Goshin & Byrne, 2012; Krishnan et al.,
2013; Meyer, Qiu, Chen, Larkin, & Altice, 2012). In the current opioid epidemic, where the
majority of opioid overdoses are due to PSU (Ruhm, 2017), understanding the factors which link
vulnerable populations to health care is a pressing public health concern. To that end, the current
research aims to (1) examine pre-incarceration PSU opioid patterns as predictors of post-release
health service utilization, and (2) identify the significant correlates of traditional and vulnerable
domains as predictive of post-release emergency room and outpatient care. It is expected that
PSU patterns that are associated with poor mental and physical health comorbidities will engage
in post-release care, most notably ER care. It is also hypothesized that vulnerable domains will be
robust predictors of post-release service utilization.

4.2
4.2.1

Methods
Sample
Data from the current sample are from the Criminal Justice Kentucky Treatment

Outcome Study (CJKTOS). The study is a state-mandated treatment outcome study of
Department of Corrections (DOC) substance abuse programming (SAP), ongoing since 2005 in
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conjunction with the University of Kentucky’s Center on Drug and Alcohol Research. The SAP is
available to individuals in KY prison, jails, and community custody programs with a self-report
of substance use history and 24-months remaining before parole or release. The program is 6months in duration and follows a therapeutic community model of treatment (De Leon, 2000).
Within the first two weeks of entering SAP, a baseline assessment is given by trained
DOC staff. Consent to baseline assessment is part of the DOC consent to treatment. During the
baseline assessment, individuals are asked about their desire to take part in a follow-up survey
and provide consent to be contacted along with follow-up information. Twelve months postrelease, a proportionate stratified sample of those who consented to follow-up are contacted via
telephone for an interview by university staff using computer assisted software. There were no
significant differences between the SAP population as a whole and those included in follow-up.
Among individuals who consent to follow-up, a random sample proportionate to the number of
males and females released from each institution are selected for inclusion with a yearly target of
350 individuals. Follow-up rates were 80% (2015), 83% (2016), and 84% (2017). Persons were
ineligible for follow-up if the moved out of the state or were deceased. All data were encrypted,
and a certificate of confidentiality was obtained. The study is approved by the University
Institutional Review Board.
The current sample included individuals from the 2015-2017 follow-up surveys, and their
linked baseline assessment information, for a total of 1,044 individuals. The sample was limited
to persons who participated in prison or jail-based SAPs (n=982). Further, individuals had to have
reported the use of an opioid (i.e., heroin, nonprescribed prescription opiate, illicit suboxone or
methadone) in the 12-months prior to incarceration and must have reported using more than one
substance in the 30-days prior to incarceration (e.g., polysubstance use). The final sample
included 501 individuals who met the study inclusion criteria.
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4.2.2

Measures
Variables measuring polysubstance use, traditional, and vulnerable domains were from

the baseline assessment data. The health care utilization variables were from follow-up
assessments conducted 12-months post-release.
4.2.2.1

Polysubstance use variables.

Polysubstance use was measured through the use of latent profiles. Continuous variables
measuring the number of days in the 30-days prior to incarceration individuals engaged in the use
of alcohol, cocaine, marijuana, heroin, nonprescribed prescription opiates, illicit suboxone,
amphetamines, and tranquilizers were included in the creation of latent profiles. The profiles used
in the current sample were obtained through replication of a prior larger baseline-only sample
from CJTKOS (see paper 1) where a six-profile solution was identified. Posterior probabilities
from the previously identified profiles were applied to the current data in order to determine if the
profiles replicate, a process referred to as validation (Pastor, Barron, Miller, & Davis, 2007).
The six-profile model successfully converged, and fit indices indicated that this model
was the best fit for the current data (see Table 4.1). Examination of the profiles indicated that they
remained the same in terms of substantive meaning and structure from the six-profiles identified
in the earlier study. Individuals were assigned to their profile of most likely membership, and
membership is independent in that individuals could not belong to more than one profile. The
final six profiles include: Primarily Alcohol, Primarily Heroin, Low PSU, High PSU, Primarily
Suboxone, and Stimulant-Opioid (see Table 4.2).
Profiles were given a descriptive profile abbreviation which are used to refer to the
profiles in the remainder of the research. Profile 1, Primarily Alcohol P1, described 6.2% of the
sample and was characterized by near daily alcohol use with co-use of marijuana and opiates.
Approximately 16% of the sample was characterized by Primarily Heroin P2, with predominately
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heroin use and co-use of marijuana and opiates. The largest profile (42.9%) was Low PSU P3
whom did not have near daily use of any substances but somewhat regular use of marijuana and
opiates. Profile 4, with 15% of the sample, was characterized by High PSU of opiates and near
daily use of tranquilizers along with co-use of alcohol and marijuana. The Primarily Suboxone P5
profile (8.6%) included near daily use of illicit suboxone and co-use of marijuana and opiates.
Lastly, Stimulant-Opioid P6 described the near daily cocaine and co-use of opiates, heroin, and
marijuana indicated by 11% of the sample in profile six.
4.2.2.2
4.2.2.2.1

Traditional domain variables.

PREDISPOSING.

Age was measured continuously. Marital status was collapsed such that married was
compared to all other statuses. Education was measured continuously, with GED equivalating 12 th
grade completion. Pre-incarceration employment status was dichotomous such that
unemployed=1. Gender (1=male) and race (1=white) were measured dichotomously.
4.2.2.2.2

ENABLING.

Pre-incarceration income was not available, however a measurement of economic
hardship was included. A summative scale of eight indicators (1=yes, 0=no) adapted from the
Survey of Income and Program Participation (Beverly, 1999; 2001) measuring 12-month prior to
incarceration hardships such as, “Did you or someone in your household need to see a doctor or
go to the hospital but weren’t able to because of financial reasons?” The scale includes five items
measuring difficulty meeting basic living and three items measuring difficulty affording health
care (R:0-8, α=0.87).
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4.2.2.2.3

NEED.

Measures of health statuses were included. Chronic pain history was measured
dichotomously (1=yes) via a question: “Chronic pain persists or recurs for 3 months or longer. It
typically includes pains like what you get from arthritis, fibromyalgia or unhealed injuries. It does
not include minor headaches, or temporary pain from minor injuries. Have you had serious
chronic pain persisting or recurring for 3 months or longer during the 12 months prior to this
incarceration?” The number of poor mental health days and physical health days were measured
continuously by asking individuals about the number of days in the 30 days prior to incarceration
their physical health and mental health (separately) were not good.
4.2.2.3
4.2.2.3.1

Vulnerable domain variables.

PREDISPOSING.

Pre-incarceration homelessness was dichotomously measured (1=yes). The length of each
individual’s incarceration was calculated. Rurality was measured using the National Center for
Health Statistics urban-rural coding scheme (Ingram & Franco, 2004) to code the county
individuals lived in prior to incarceration. These were dichotomized (rural=1) such that counties
with populations more than 250,000 were considered urban (urbanization levels: large metro,
central & fringe, medium metro), compared to smaller counties (urbanization levels: small metro,
micropolitan, noncore).
4.2.2.3.2

ENABLING.

Individuals self-reported if they had a learning disability (1=yes). Recovery support was
measured dichotomously (1=yes) via the question; “In the 30 days prior to this incarceration, did
you have contact with family or friends who were supportive of your recovery?”

84

4.2.2.3.3

NEED.

Injection drug use was measured dichotomously regarding lifetime history (1=yes). HCV
was self-reported (1=yes). Depression was measured using a modified dichotomous version of the
Patient Health Questionnaire-9 (R:0-9, α= 0.93). Anxiety was measured via a modified
dichotomous version of the Generalized Anxiety Disorder-7 (R: 0-7, α=0.97).
4.2.2.4

Health care utilization variables.

Two follow-up variables measured health care utilization dichotomously. Specifically,
the use of the emergency room and outpatient care in the 12-months post-release were included as
the dependent variables of interest.
4.2.3

Analytic plan
Descriptive and bivariate statistics were examined on all variables of interest and are

included in Table 4.3. Fisher’s exact and ANOVA tests examine the significance of the variables
by the polysubstance latent profiles. Variable selection techniques were used for multivariate
models. Variables significantly correlated with either of the outcome variables in a correlation
matrix (not shown) at the p<.05 level were included in the models.
Multivariate logistic regression models were used to predict emergency room visits
(Table 4.4) and outpatient visits (Table 4.5) using a stepwise technique. The stepwise approach
enters latent profiles first, followed by traditional domain variables, and vulnerable domain
variables as the full model. All analyses were completed using Stata 15.1 SE. Tests of
multicollinearity revealed no issues with variance inflation factors less than 2.0. Final models
were significant and provided best model fit.
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4.3
4.3.1

Results
Descriptive and bivariate statistics
Table 4.3 includes descriptive statistics with results from Fisher’s exact and ANOVA

tests. On average, individuals were 33 years old, with 12 years of education, white, and
unemployed prior to incarceration. The sample was primarily male. Approximately one-fifth were
married. Individuals reported an average of two economic hardships. Nearly one-third reported
chronic pain prior to incarceration. Individuals reported an average of 7 days of poor physical
health and 12 days of poor mental health, with substantial variation as evident by the standard
deviations.
One-fifth of the sample was homeless prior to incarceration. Individuals were
incarcerated an average of two years. Half of the sample lived in rural counties prior to
incarceration. One-quarter of the sample reported a learning disability and 30% reported having
no contact with friends or family who were supportive of their recovery. The majority (61.9%)
had lifetime histories of IDU. Fourteen percent self-reported HCV. Individuals, on average, met
the criteria for mild to moderate depression and anxiety as indicated by PHQ-9 and GAD-7 scores
(Spitzer, Kroenke, Williams, & Group, 1999; Spitzer, Kroenke, Williams, & Löwe, 2006).
Emergency room utilization was engaged by 45% of the sample, and 42% reported outpatient
visits in the 12-months after release.
In order to better understand the intersection of PSU and health, all variables were
examined by PSU profile. Fisher’s exact and ANOVA tests examine significant bivariate
differences across profiles. Post-hoc Tukey tests after significant ANOVA results were also
explored. Profiles were not significantly different on any of the traditional domain variables.
Significant differences were found on vulnerable domain variables.
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Specifically, individuals in the Primarily Heroin P2 and Stimulant-Opioid P6 profiles
were more likely to be homeless (p<.02). Tukey results indicated significant differences of
incarceration length among the Primarily Heroin P2 and High PSU P4 profiles (p<.05). The
Primarily Heroin P2 profile was least likely to live in a rural county prior to incarceration (24%),
while the Primarily Suboxone P5 profile was most likely to live in a rural county prior to
incarceration (79%; p<.001). Significant differences of IDU history existed such that the
Primarily Alcohol P1 and Low PSU P3 profiles were less likely to report IDU (p<.001). These
profiles were additionally less likely to report HCV serostatus (p<.03).
Significant differences existed between profiles on both mental health variables of
depression and anxiety. The Low PSU P3 and High PSU P4 profiles differed significantly on
both variables (p<.05), such that the High PSU P4 profile had greater symptomology. The High
PSU P4 profile also had significantly greater depression symptoms when compared to the
Primarily Suboxone P5 profile in post-hoc tests (p<.05).
Additional significant differences were found by profile’s post-release utilization of ER
care. Post-release care utilization indicated that the High PSU P4 and Stimulant-Opioid P6
profiles utilized the ER most often. Profiles did not significantly differ by outpatient care
utilization.
4.3.2

Multivariate models
Tables 4.4 and 4.5 contain multivariate logistic regression models predicting post-release

service utilization. Latent profiles were entered first, followed by relevant traditional and
vulnerable domain variables. In the bivariate correlations, no variables from the enabling
traditional or vulnerable domain were significantly associated with either of the outcome
variables. All other factors were represented in each domain.
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In Model 1 of Table 4.4, the latent profile of High PSU P4 was significantly associated
with increased ER utilization (AOR: 1.90, p<.01). Traditional domain variables were entered in
Model 2. High PSU P4 remained significant, and the traditional predisposing factor of gender was
significant, such that males were less likely to report ER use (AOR: 0.68; p<.05). In the final
Model 3 of Table 4 once vulnerable domain variables were entered, several variables were
significant predictors of post-release ER utilization. Individuals categorized by Primarily Heroin
P2 PSU patterns emerged as less likely to use the ER (AOR: 0.41, p<.01). Those with High PSU
P4 patterns remained more likely to use the ER post-release (AOR: 1.76, p<.05). While gender
was significant in Model 2, no traditional domain variables were significant in the final model
once vulnerable domains were included. In the vulnerable domain, individuals from rural counties
were less likely to utilize ER care (AOR: 0.47, p<.001). Persons with HCV were more than twice
as likely to use the ER post-release (AOR: 2.84, p<.001).
Outpatient care utilization is examined in Table 4.5. In Model 1, the Primarily Suboxone
P5 group was less likely to utilize outpatient care (AOR: 0.48, p<.05). However once traditional
domain variables were entered in Model 9, this association was no longer significant, and in the
full Model 10 none of the latent profiles were significant predictors of outpatient care utilization.
In the traditional domain, older individuals were more likely to use outpatient care (AOR: 1.03,
p<.01). Individuals who were unemployed prior to incarceration (AOR: 0.50, p<.001) and males
(AOR: 0.42, p<.001) were less likely to report outpatient visits post-release. In the vulnerable
domain, pre-incarceration depression scores were significantly predictive of outpatient visits such
that with increasing scores individuals were more likely to report outpatient care (AOR: 1.07,
p<.01).
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4.4

Discussion
The current study sought to examine pre-incarceration polysubstance opioid use as a

predictor of post-release health care using the Behavioral Model for Vulnerable Populations
(Gelberg et al., 2000). Multivariate logistic regressions examined latent PSU profiles, traditional,
and vulnerable domains as predictive of 12-month post-release utilization of the ER and
outpatient visits. PSU patterns significantly predicted ER visits, but not outpatient visits. Overall,
this research contributes to the existing literature documenting the vulnerable domain as a robust
predictor for justice-involved populations post-release service utilization (Nowotny, 2017; Oser,et
al., 2016; Victor, et al., 2018).
It was hypothesized that PSU patterns that were associated with worse physical and
mental health symptoms would be more likely to engage with post-release care, particularly ER
services. The High PSU profile had significantly worse mental health and more pronounced
physical health concerns such as chronic pain. Individuals categorized by this PSU pattern were
more likely to use the ER post-release. Prior research has indicated that more diverse PSU
patterns are associated with worse physical and mental health (Betts et al., 2016, 2015; Borges,
Walters, & Kessler, 2000; Connor, Gullo, White, & Kelly, 2014; Patra, Fischer, Maksimowska, &
Rehm, 2009). That these individuals were most likely to use intensive and expensive sources of
care may indicate that they lacked regular sources of care, or outpatient care was insufficient at
addressing the depth of their comorbidities. Forty-seven percent of individuals in the High PSU
P4 group report using outpatient care post-release. However, the current analyses lack the
information to garner if individuals first tried outpatient care, were referred to more intensive
solutions, or if they simply experienced more crises of care leading them to utilize multiple forms
of post-release care.
One profile emerged as less likely to access care. Specifically, the Primarily Heroin P2
group was less likely to access ER care. This is slightly disconcerting considering this profile had
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high rates of prior homelessness, IDU, and HCV-- factors associated with increased ER
utilization (French, McGeary, Chitwood, & McCoy, 2000; Kerr et al., 2005; Ostertag, Wright,
Broadhead, & Altice, 2006). Research has found that despite high need, persons who inject drugs
were less likely to receive care on occasions when care was needed (Chitwood, McBride, French,
& Comerford, 1999). Persons who inject drugs are less likely to utilize health care for various
reasons including insurance status, distrust in physicians/health systems, fear of law enforcement
involvement, or lack of desire for treatment (McCoy, Metsch, Chitwood, & Miles, 2001; Neale,
2008; Ostertag et al., 2006; Seal et al., 2001).
None of the PSU profiles emerged as significant predictors of outpatient care. Research
has found that persons who use drugs are less likely to utilize outpatient services or seek regular
care (Knowlton et al., 2001; Laine et al., 2001). A study of individuals who inject opioids found
that persons were less likely to use outpatient services but more likely to use ER services (Chen,
Huang, Yeh, & Chien, 2015). Factors beyond substance use alone appear to be more important
predictors of outpatient service utilization indicating substance use patterns likely provide more
insights into health crises through the use of ER care.
The second aim of the current research was to identify the significant correlates within
traditional and vulnerable domains of the Behavioral Model for Vulnerable Populations (Gelberg
et al., 2000) as significant predictors of post-release health service utilization. It was expected that
vulnerable domains would be robust predictors of utilization, and this was found in the case of
ER care, and to a lesser extent for outpatient visits.
To consider ER utilization, vulnerable domain variables of rurality and HCV serostatus
were significant correlates. Individuals returning home to rural counties could be less likely to use
ER care simply due to availability. Kentucky has 120 counties, several of which have no hospitals
or one hospital per county, which may be difficult to access given rural travel and infrastructure
barriers (Hare & Barcus, 2007). The current research adds support to findings that previously
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justice-involved persons with HCV are more likely to utilize the ER (Humphreys, Ahalt, StijacicCenzer, Widera, & Williams, 2018; Thakarar, Morgan, Gaeta, Hohl, & Drainoni, 2015) indicating
that justice-involved persons with HCV have chronic health needs and justice-involvement
provides an opportunity for treatment interventions (Rich, Allen, & Williams, 2014).
The vulnerable domain variable of depression was a significant predictor of outpatient
visits. This is a hopeful finding, indicating that individuals with increasing severity of depression
are linking to care. Often, individuals with increased mental health needs face a variety of
negative outcomes post-release while attempting to navigate returning to community life and
mental health needs (Binswanger et al., 2012; Hopkin, Evans-Lacko, Forrester, Shaw, &
Thornicroft, 2018). Evidence suggests that individuals who are exposed to treatment during
incarceration may be more likely to engage in care post-release, including seeking care for
different health needs than those for which they previously received treatment (Knowlton et al.,
2001). As applied in the current study, individuals’ participation in the SAP could have primed
them for engagement in treatment for their depression post-release. Individuals may also be more
aware of their treatment needs, and research has found individuals with greater perceived mental
health treatment need were more likely to be engaged in post-release mental health care
(Hamilton & Belenko, 2016). Further, research has indicated that interventions and services
aimed at the period of transition from prison to community can improve mental health service
utilization post-release (Hopkin et al., 2018). While the current research is only able to report that
individuals with increased depression scores were more likely to access some form of outpatient
care, it is worth mentioning the KY DOC social service clinician role in reentry. Post-release,
individuals with substance use and mental health histories (i.e., those who participated in SAP),
are assigned to a social service clinician in addition to their parole officer. The social service
clinicians assist in linking justice-involved individuals to services post-release, to include
behavioral health services.
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For ER utilization, no traditional domain variables were significant highlighting the need
for studies to include both general population factors as well as those unique to vulnerable
populations when considering health service utilization. In models predicting outpatient service
utilization, the traditional domain factors of age, unemployment, and gender were significant
predictors. Extant research exists to support these findings. Longer sentences have led to an aging
prison population, with more prodigious health needs and higher rates of chronic conditions
(Williams et al., 2010). Older individuals, in general, as well as those with substance and justice
histories (Gelberg et al., 2000; Nowotny, 2017; Williams et al., 2013) are more likely to engage
in health service utilization post-release.
Following release, men are less likely to access health services (Hamilton & Belenko,
2016; Kouyoumdjian et al., 2018; Oser et al., 2011) and to take longer to access regular care, such
as outpatient care (Kouyoumdjian et al., 2018). Finally, individuals who reported unemployment
prior to their incarceration were less likely to use outpatient care. This may be a latent indicator of
economic hardship, or individuals who lacked employment prior to incarceration may be more
likely to have difficulty finding employment post-release. Employment offers financial means to
access care as well as potential access to health insurance.
Collectively, the findings highlight the utility of PSU as a unique predictor of health
services and indicate the potential for health service interventions during incarceration. PSU
patterns were based on pre-incarceration behaviors indicating a captive period of incarceration
where individuals could receive interventions and appropriate health services. In the case of
certain PSU groups, such as the High PSU P4 profile, this could include confirming that
insurance is obtained and linking to regular sources of care since these individuals were more
likely to consume more cost-intensive health services. For other groups, such as Primarily Heroin
P2 who were less likely to seek health services, interventions could include the opportunity to
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meet community health providers during incarceration in order to assist in barriers such as
physician mistrust or health service navigation training.
4.4.1

Limitations
The current research has limitations which future research should seek to improve. The

sample was from a single southern state, and some of the findings may not translate to other
locales. Further, the traditional and vulnerable domains included were limited to those relevant to
the current sample as well as by variables included on the baseline assessments. Future research
examining service utilization in other states, or preferably multi-state, with population relevant
domain variables are necessary. The data are based on self-reports of pre-incarceration behaviors
and post-release use of health care. Generally, self-reports are a demonstrated valid source of
health service use data (Carroll, Sutherland, Kemp-Casey, & Kinner, 2016) but linkage to health
administration data could yield additionally important findings. Finally, the current research only
included dichotomous measures of two health-services and future research should examine other
health-services (e.g., alternative therapies), number of visits, and the circumstances related to care
(e.g., specific health need).
4.4.2

Conclusions
The Behavioral Model for Vulnerable Populations in combination with consideration of

PSU opioid patterns revealed important insights into the health service utilization of individuals
reentering the community after release from prison and jail. Specific PSU patterns and vulnerable
domain variables were efficient predictors of ER care, while traditional and vulnerable domain
variables predicted outpatient care. The vulnerabilities associated with justice-involvement and
PSU are important to this population’s utilization of health services. Implications of the current
research indicate that certain PSU populations are at-risk of having their health needs unmet,
particularly those who have histories of homelessness and IDU. Further, former justice-involved
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populations with high health needs of HCV would benefit from assisted coordination of care to
ensure their continuum of care is not disrupted and individuals have access to a regular source of
care. The health of justice-involved populations shapes health inequities at the community level
(Wildeman & Wang, 2017) and addressing health needs including service utilization of this
population will improve public health outcomes at large.
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Table 4.1 Fit statistics for latent profile validation analysis
6,569 Baseline
Sample
AIC
BIC

501 Follow-Up Cohort

Number of
AIC
BIC
Profiles
1
409677.5
409786.1
30960.7
31028.2
2
402295.7
402465.5
30073.9
30179.3
3
400521.7
400752.6
29921.7
30065.0
4
400005.1
400297.1
30231.8
30413.1
5
394654.1
395007.2
30127.9
30347.1
6
393898.7
394312.9
29810.8
30068.0
Notes: AIC= Akaike’s information criterion; BIC= Bayesian Information
criterion; bolded indicates selected latent profile
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Table 4.2 Latent profile conditional means for polysubstance opioid use (n=501)
Descriptive profile
abbreviation
Latent Profile
indicators: Prior
30- day use
Alcohol
Cocaine
Marijuana
Heroin
Suboxone
Opiates
Amphetamines
Tranquilizers

Profile 1

Profile 2

Primarily
Alcohol
P1

Primarily
Heroin P2

27.66
3.08
13.95
1.77
1.45
11.14
6.82
2.85

3.81
1.25
11.24
28.85
2.71
15.14
5.77
4.29

Profile 3

Profile
4
Low PSU High
P3
PSU
P4

Profile 5

Profile 6

Primarily
Suboxone
P5

Stimulant
-Opioid
P6

2.80
0.62
11.98
0.89
1.41
16.51
8.09
2.77

10.27
1.97
13.68
7.45
9.36
19.79
9.84
28.71

6.15
1.22
13.67
1.94
28.49
13.30
8.37
4.23

8.68
28.13
14.90
13.55
7.97
17.21
6.09
11.11

Profile Prevalence
6.19%
15.97%
42.91%
Note: shading highlights most prevalent substances

15.17%

8.58%

11.18%
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Table 4.3 Characteristics of study population (n=501)
High PSU
P4

Primarily
Suboxone
P5

33.84
(8.61)
12.06
(1.65)
77.42
70.97

30.54
(6.71)
11.77
(2.10)
90.00
38.75

32.99
(7.70)
11.83
(2.17)
86.05
34.42

33.33
(8.82)
12.21
(2.53)
86.84
35.53

31.81
(6.97)
11.65
(1.97)
83.72
20.93

32.55
(6.91)
11.78
(1.81)
75.00
46.43

.14

72.65
21.36
2.10
(2.52)
30.34

80.65
12.90
2.42
(2.78)
32.26

68.75
22.50
2.24
(2.75)
26.25

72.09
20.93
1.91
(2.40)
29.30

67.11
19.74
2.25
(2.57)
44.74

79.07
30.23
1.70
(2.11)
23.26

78.57
21.43
2.61
(2.67)
25.00

.62
.45
.34

7.40
(11.97)
11.54
(13.80)

9.42
(13.45)
13.52
(14.15)

7.15
(12.12)
12.52
(14.30)

6.47
(11.35)
10.12
(13.32)

9.25
(12.88)
15.31
(14.21)

8.32
(12.03)
9.51
(13.83)

6.96
(12.01)
10.91
(13.54)

.50

20.16
2.23
(1.74)

16.13
2.60
(2.36)

28.75
1.71
(1.25)

14.42
2.21
(1.72)

23.68
2.61
(1.54)

16.28
2.17
(1.46)

30.36
2.41
(2.23)

.02
.02

52.69
25.75

58.06
29.03

23.75
28.75

59.53
21.40

56.58
26.32

79.07
34.88

39.29
28.57

.001
.44

29.74

29.03

30.00

30.23

31.58

25.58

28.57

.99

61.88
14.17
4.44
(3.52)
3.71
(3.23)

48.39
9.68
4.26
(3.55)
3.84
(3.36)

81.25
23.75
5.07
(3.43)
3.51
(3.18)

50.70
9.77
4.01
(3.53)
3.30
(3.22)

71.05
18.42
5.61
(3.31)
4.68
(3.12)

65.12
18.60
3.35
(3.48)
3.74
(3.32)

69.64
10.71
4.55
(3.46)
4.14
(3.15)

.001
.03
.002

46.51

53.57

.01

27.91

44.64

.18

Dependent
Variables
Emergency
45.41
29.03
33.75
44.65
60.53
room visits
Outpatient
41.92
45.16
33.75
44.65
47.37
visits
Note: p-values obtained through ANOVA and Fisher’s exact tests
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p-value

Low PSU
P3

32.55
(7.67)
11.87
(2.13)
84.83
64.87

Stimulant
-Opioid
P6

Primarily
Heroin P2

Anxiety

Primarily
Alcohol
P1

Education
level
White
Unemploye
d
Male
Married
Economic
hardship
Chronic
pain
Physical
health days
Mental
health days
Vulnerable
Domain
Homeless
Years
incarcerate
d
Rural
Learning
disability
No
recovery
support
IDU
HCV
Depression

Total
Sample
Traditional
Domain
Age

.70
.17
.16

.07

.07

.04

Table 4.4 Stepwise logistic regression predicting emergency room visits; Adjusted
odds ratios (standard errors) reported (n=501)
Latent Profiles
Primarily Alcohol P1
Primarily Heroin P2
High PSU P4
Primarily Suboxone P5
Stimulants-Opioid P6
Traditional domains
Age
Unemployed
Male
Chronic pain
Mental health days
Vulnerable domains
Rural
HCV
Depression

Model 1

Model 2

Model 3

0.51 (0.21)
0.63 (0.17)
1.90 (0.52)**
1.08 (0.36)
1.43 (0.43)

0.53 (0.22)
0.64 (0.18)
1.86 (0.51)*
1.15 (0.39)
1.47 (0.45)

0.50 (0.22)
0.41 (0.12)**
1.76 (0.50)*
1.21 (0.43)
1.28 (0.40)

1.01 (0.01)
0.85 (0.17)
0.68 (0.14)*
1.21 (0.26)
1.00 (0.01)

1.01 (0.01)
0.87 (0.18)
0.69 (0.15)
1.18 (0.26)
0.99 (0.01)
0.47 (0.10)***
2.84 (0.84)***
1.00 (0.03)

Model X2
16.54**
23.45**
48.83***
Psuedo R2
0.0239
0.0340
0.0707
Note: Latent profile 3, low PSU is reference group; significance indicated by
*p<.05, **p<.01, ***p<.001
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Table 4.5 Stepwise logistic regression predicting outpatient visits; Adjusted odds ratios
(standard errors) reported (n=501)
Latent Profiles
Primarily Alcohol P1
Primarily Heroin P2
High PSU P4
Primarily Suboxone P5
Stimulants-Opioid P6
Traditional domains
Age
Unemployed
Male
Chronic pain
Mental health days
Vulnerable domains
Rural
HCV
Depression

Model 1

Model 2

Model 3

1.02 (0.39)
0.63 (0.17)
1.11 (0.30)
0.48 (0.17)*
1.00 (0.30)

1.11 (0.45)
0.60 (0.17)
1.02 (0.29)
0.56 (0.21)
0.99 (0.31)

1.10 (0.45)
0.58 (0.18)
0.96 (0.28)
0.56 (0.21)
0.98 (0.31)

1.03 (0.01)*
0.49 (0.10)***
0.39 (0.09)***
1.13 (0.25)
1.00 (0.01)

1.03 (0.01)*
0.50 (0.10)***
0.42 (0.09)***
1.09 (0.24)
1.00 (0.01)
1.11 (0.23)
0.99 (0.29)
1.07 (0.03)*

Model X2
7.76
55.40***
60.10***
Psuedo R2
0.0114
0.0813
0.0882
Note: Latent profile 3, low PSU is reference group; significance indicated by
*p<.05, **p<.01, ***p<.001
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Figure 4-1Behavioral Model for Vulnerable Populations (Gelberg, Andersen, & Leake,
2000) as applied in current research
Predisposing
Traditional Domain

v

Age
Marital status
Education
Employment status
Gender
Race
Vulnerable Domain
Homelessness
Years incarcerated
Rurality

Enabling

Need
Traditional Domain

Traditional Domain

Chronic Pain
# of poor physical
health days
# of poor mental
health days

Economic
hardship

Vulnerable Domain

Vulnerable Domain

IDU
HCV
Depression
Anxiety

Recovery support
Learning disability

Measured pre-incarceration
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Health Behavior
Health Service Utilization
Emergency room
Outpatient

CHAPTER 5. CONCLUSION
The current research explored the topic of polysubstance opioid use among a justiceinvolved sample, to include the effect of polysubstance use (PSU) on subsequent reentry
outcomes of relapse and health service utilization. Chapter 2 determined the polysubstance opioid
patterns that were prevalent among a recently incarcerated population through the use of latent
profile analysis. Chapter 3 examined how post-release relapse was affected by pre-incarceration
polysubstance use patterns, and was guided by the Behavioral Model for Vulnerable Populations
(Gelberg, Andersen, & Leake, 2000). Chapter 4 explored latent profiles along with the vulnerable
and traditional domains of the Behavioral Model for Vulnerable Populations as predictors of
emergency room and outpatient visits in the 12-months post-release.
The research presented here makes four significant contributions to the literature. First,
the research is among the first known to examine polysubstance opioid use patterns among a
justice-involved population. Secondly, the use of 30-day continuous indicators in latent profile
analysis as opposed to latent class analysis provides a unique methodological contribution and
yielded more detailed information about PSU patterns. Third, the results indicate a continuum of
risk according to PSU patterns which differentially affect reentry processes among an already
vulnerable population. Finally, through the use of the Behavioral Model for Vulnerable
Populations, the current research further adds to literature advocating for the consideration of
vulnerable population specific factors when examining health services as well as expanding use
of the model to the health outcome of relapse.

5.1
5.1.1

Key Findings
Heterogeneity of Substance Use among a Justice-Involved Sample
The current research found distinct profiles of PSU among a justice-involved sample with

recent history of opioid use. While previous research had indicated that more severe drug use and
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PSU was likely among justice populations (Betts et al., 2016; Green, Black, Serrano, Budman, &
Butler, 2011; Kubiak, 2004; Lo & Stephens, 2000), it was unclear to what extent preincarceration PSU patterns of justice populations were similar or differed from general
populations. Chapter 2 revealed six distinct profiles of PSU opioid use in the current sample.
These profiles replicated in a second sample in Chapters 3 & 4 as well. While the PSU patterns
may be unique to Kentucky’s justice-involved population, the findings revealed that compared to
general populations, PSU among justice-involved populations is more severe. For example, the
Low-Use profile- those with the least amount of PSU- reported an average of 14 days of opiate
use, while general population research of individuals who misuse opiates cite an average of 7
days of prior 30 (NSDUH, 2017).
It was expected that PSU justice populations would have additionally severe physical and
mental health comorbidities, given already high prevalence rates of justice populations and
research indicating PSU populations have a high comorbidity as well (Borges, Walters, &
Kessler, 2000; Connor, Gullo, White, & Kelly, 2014; Feaster et al., 2016; Mallik-Kane & Visher,
2008; Quek et al., 2013; Wu et al., 2011). This hypothesis was largely supported, as the profiles
with the most diverse (e.g., more substances) patterns of substance use were more likely to have
poor physical health, depression, and anxiety (Chapter 2). Collectively, the diverse profiles of
High PSU and Stimulant-Opioid accounted for nearly 30% of the total sample- indicating that
among justice-involved populations high-risk PSU with health comorbidities may be more
common than in general populations.
5.1.2

Methodological Innovations
The current research was among the first to utilize continuous indicators in creation of

latent profiles in order to provide more nuanced insights to the phenomena of PSU. As detailed in
the systematic review of Chapter 1, the majority of studies of PSU among persons who use
opioids rely on dichotomous indicators and latent class analysis. The current research limited the
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samples to individuals who reported using more than one substance on a given day- thus
including individuals with inclinations toward PSU by design. Further, the use of continuous 30day indicators revealed greater details to PSU patterns than dichotomous indicators alone. For
example, in Chapter 2 findings from LPA reported that the Stimulant-Opioid P6 had an average
of 10 days of alcohol use, 27 days cocaine use, 18 days marijuana use, 15 days heroin use, 9 days
illicit Suboxone use, 18 days opiate use, 11 days amphetamines use, and 11 days of tranquilizers
use. With this information it is apparent that 10-25 days of the month individuals in this profile
are co-using one or more substances. If these had been measured dichotomously through yes/no
use in the previous month, the risk behavior of the Stimulant-Opioid P6 group would have been
underestimated and not fully understood. The use of continuous indicators in future research is
imperative to advancing more detailed understandings of PSU.
5.1.3

Continuum of Risk of PSU
The collective findings indicated a continuum of risk to exist among PSU. In Chapter 2,

risk was inherent to the profiles. That is, the profiles varied from a Low-Use (little PSU) to highrisk PSU profiles (i.e., High PSU) where co-use of known overdose combinations (e.g.,
tranquilizers and opiates) was occurring more than 2/3 of the month. Chapter 3 explored the
relationship between PSU and post-release relapse. For post-release relapse, risk was highest
among individuals with Primarily Alcohol and Primarily Suboxone PSU patterns. Finally, in
Chapter 4, heterogeneity of risk was found among individuals post-release health service
utilization such that certain profiles were less likely to access care (i.e., Primarily Heroin) while
others were more likely (i.e., High PSU).
When considered together, the findings indicate that risk of adverse outcomes differ by
PSU patterns. These findings add to literature suggesting that recovery pathways differ by
substances (Castro, Barrington, Walton, & Rawson, 2000; Hser, 2007), and would go further by
suggesting that pathways differ by preferred combinations of substances. The findings in Chapter
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4 suggest that understanding pre-incarceration substance use patterns can assist in understanding
the type of post-release care individuals are likely to need. In Chapter 2, it was found that
individuals were more likely to engage in High PSU patterns if they had low levels of education,
more days of poor physical health, higher anxiety symptoms, and histories of injection drug use.
In Chapter 4, this profile was revealed to be most likely to use emergency room care, which has
significant financial ramifications. Collectively, the findings indicate that while all PSU carries
inherent risk there is a continuum of risk by which PSU patterns can be considered.
5.1.4

Importance of Vulnerability
The use of the Behavioral Model for Vulnerable Populations in Chapter 4 indicated the

continued importance of considering variables unique to vulnerable populations when examining
health service utilization. In the model predicting emergency room care, the latent profiles and
vulnerable domain variables were significant predictors of utilization. For outpatient visits, the
vulnerable domain variable of HCV was a significant predictor. The importance of vulnerable
domain variables is further evident in the Chapter 4 block models examining emergency room
utilization, such that once vulnerable variables were entered in the complete model, the traditional
variables were no longer significant. Failure to account for vulnerable population specific
variables could improperly attribute predictors of service utilization.
Further, the current research expanded the use of the Behavioral Model for Vulnerable
Populations to post-release health behaviors by examining post-release relapse. Only one other
study utilized the conceptual model to predict post-release relapse, and that research did not
stratify variables according to traditional or vulnerable domains (Krishnan et al., 2013). In
addition to latent profiles, both traditional and vulnerable domain variables were significant
predictors of post-release relapse further highlighting the importance of modeling these domains
as specific to the populations they consider.
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5.2

Implications and Real-World Considerations
The current research yielded several implications for policy and practice. These ideas

have been developed in Chapters 2-4, with specific details regarding possible interventions for
each PSU profile detailed in Chapter 2. However, it is important to again highlight the
overarching idea that PSU screening is an important tool that can be used to funnel individuals to
appropriate interventions. This is particularly relevant for justice-involved individuals who face
periods of population isolation during incarceration, and criminal justice venues provide an
important opportunity for intervention with at-risk populations.
Substance use treatment programs within prisons and jails that provide baseline
assessments, such as the KY SAP detailed in this dissertation, could create profile identification
tools. For example, with sufficient replication in future justice populations, individuals who meet
the criteria for certain PSU profiles based on responses to baseline assessment questions would be
‘flagged’ so that they could be funneled into appropriate interventions. While replication of the
current study (Chapter 2) is necessary to determine if justice-involved PSU patterns replicate on a
local or national level, there are certain patterns which at this point are known to exist in multiple
populations- the High PSU and Stimulant-Opioid profiles (see details in Chapter 2) based on
these findings and existing research (Harrell, Mancha, Petras, Trenz, & Latimer, 2012; Kuramoto,
Bohnert, & Latkin, 2011; Meacham et al., 2016; Roy, Richer, Arruda, Vandermeerschen, &
Bruneau, 2013). Determining appropriate interventions for these profiles would provide a good
starting point for PSU intervention development.
Further, the current research has demonstrated efficacy of measuring and considering
PSU as an important factor of post-release behavior. PSU profiles were significant predictors of
post-release relapse and ER utilization. That PSU behaviors offer understanding to post-release
behaviors is a novel contribution. In conjunction with the ideas above, these findings indicate that
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interventions can be tailored both pre-release and continue into the community in order to
improve outcomes for justice-involved populations.
Finally, the research findings here support the idea that as a discipline there is a need to
expand conceptualizations of substance use beyond the ideals of primary substance. This includes
understandings of recovery, where researchers have been advocating for more dynamic
measurements of relapse (White & Ali, 2010; White, 2007). In order positively influence the lives
of individuals with substance use disorders, and in turn community health as a whole, researchers
should go beyond siloing individuals according to their primary substance. Given that individuals
often seek out PSU due to preferred effects, research stands to create more impactful change by
understanding these motivations and adjusting interventions and suggestions for policy
appropriately.

5.3

Future Directions for Research
While specific directions for future research are mentioned in each of the chapters, there

are three broad suggestions to consider which have been mentioned but are succinctly stated here.
First, there is significant heterogeneity among opioid PSU in a justice-involved population. PSU
patterns are more severe and differ from previous general population research. Future research is
needed to determine if the profiles observed here replicate, or if they are unique to KY’s justiceinvolved population.
Secondly, there is a continuum of risk among opioid PSU populations. That is, not all
profiles were at risk of adverse outcomes post-release. Tailoring interventions for at-risk profiles
during the period of justice-involvement and making appropriate linkages to care would assist in
mitigating adverse post-release outcomes.
Finally, through the process of the dissertation research it became apparent that there are
significant lapses in our current understandings of PSU, in part due to the limitations of existing
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instrumentation. Development of appropriate screening and assessment tools that can (1) measure
different types of PSU (e.g., simultaneous, regular interval), (2) provide details as to PSU patterns
including method of administration (e.g., injection, intranasal), and (3) in more real-time
circumstances (as opposed to call-back of long-periods of time) are greatly needed.

5.4

Conclusion
In the current opioid epidemic, overall life expectancy in the United States is falling

owing to increased drug overdose deaths (Larney & Hall, 2019). It is critical to recognize the role
PSU has in the current epidemic, as well as identification of individuals who are most likely to be
impacted. Individuals with justice-involvement are at pronounced risk of overdose death
following release (Binswanger, Blatchford, Mueller, & Stern, 2013). The research above has
made clear that PSU is pronounced among justice-involved populations with histories of opioid
use, placing them at great risk of adverse outcomes. Identifying at-risk PSU patterns among
justice-involved populations in order to design effective interventions is critically important.
Moreover, improving the health of justice-involved populations is crucial for better population
health nationwide.
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